https://m2.mtmt.hu/ hun 2026-05-02 01:06 JournalArticle 36487681 VALIDATED true Funding Agency and Grant Number: Wroclaw Medical University; Wroclaw Medical University, Poland [IDUB.A46B.24.002] Funding text: This research was funded by a grant from Wroclaw Medical University, Poland, number IDUB.A46B.24.002. The presented research results were funded by the Development Strategy of the Wroclaw Medical University entitled "UMW in the Light of Scientific Excellence 2024-2026." 0 false 2026-04-01T13:29:11.707+0000 2026-04-01T12:31:18.568+0000 2025-12-11T18:38:10.115+0000 true 10016470 Habon Tamás /api/author/10016470 Author Habon Tamás (Belgyógyászat, Kardiológia, Klinikai farmakológia) true 10016470 2026-04-01T12:30:37.063+0000 2026-04-01T12:30:37.063+0000 2026-04-01T12:31:19.243+0000 true 10097129 Vékony-Pap Lili /api/admin/10097129 Admin Vékony-Pap Lili (SZTE admin5) true false false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Wilk, Michał true true /api/journal/10053785 REVIEWED JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE 2308-3425 true false 10053785 false 10053785 true 2308-3425 Journal FOREIGN 12 12 484 484 2025 Heart failure (HF) remains a major challenge in cardiovascular medicine, contributing to high global rates of hospitalization and mortality. Recent research (2022–2025) has emphasized its heterogeneity, highlighting distinct phenotypes—HFpEF, HFmrEF, and HFrEF—driven by mechanisms such as chronic inflammation, myocardial fibrosis, and neurohormonal imbalance. Advances in therapy, particularly with sodium–glucose cotransporter-2 inhibitors (SGLT2i), angiotensin receptor–neprilysin inhibitors (ARNI), and iron supplementation, have reshaped treatment strategies. Moreover, the growing recognition of overlaps between HF and cardiomyopathies such as hypertrophic, Takotsubo, and amyloidosis underscores the need for integrated care. This review summarizes recent findings from leading journals, mapping the evolving understanding of HF pathophysiology and management, and outlining emerging directions for research and clinical practice. true 2025 true true true false false false GOLD 2026-04-01 false https://www.mdpi.com/journal/jcdd 0 0 0 0 0 0 0 0 0 0 0 0 16 16 Q1 false false false false 2026-01-29T10:12:39.772+0000 31 102 0 2 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 128860393 /api/authorship/128860393 Wilk, Michał 1 0.5 true false false Wilk Michał true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128860394 /api/authorship/128860394 Tymków, Rafał 2 0.5 false true false Tymków Rafał true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 30312812 /api/publicationidentifier/30312812 DOI: 10.3390/jcdd12120484 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true IDENTICAL 10.3390/jcdd12120484 https://doi.org/10.3390/jcdd12120484 false true PublicationIdentifier 30930722 /api/publicationidentifier/30930722 WoS: 001646762700001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001646762700001 https://www.webofscience.com/wos/woscc/full-record/001646762700001 false true PublicationIdentifier 31101062 /api/publicationidentifier/31101062 Scopus: 105025668654 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105025668654 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105025668654 false true PublicationIdentifier 31277467 /api/publicationidentifier/31277467 PubMed: 41440863 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 41440863 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41440863&dopt=Abstract false true SjrRating 11612619 /api/sjrrating/11612619 sjr:Q1 (2025) Scopus - Pharmacology, Toxicology and Pharmaceutics (miscellaneous) JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE 2308-3425 23 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3001 /api/classificationexternal/3001 Scopus - Pharmacology, Toxicology and Pharmaceutics (miscellaneous) true 3001 true Q1 FROM_LAST_YEAR true true Reference 70713021 /api/reference/70713021 1. Beghini 2025: 2024 update in heart failure., ESC Heart Fail., 12, p. 8, DOI: 10.1002/ehf2.14857 1 10.1002/ehf2.14857 false true Reference 70713022 /api/reference/70713022 2. Abdelhamid 2023: Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey., ESC Heart Fail., 10, p. 2773, DOI: 10.1002/ehf2.14456 2 10.1002/ehf2.14456 false true Reference 70713023 /api/reference/70713023 3. Ali 2023: Rising arterial stiffness with accumulating comorbidities associates with heart failure with preserved ejection fraction., ESC Heart Fail., 10, p. 2487, DOI: 10.1002/ehf2.14422 3 10.1002/ehf2.14422 false true Reference 70713024 /api/reference/70713024 4. Berger 2024: IL-6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 3607, DOI: 10.1002/ehf2.14959 4 10.1002/ehf2.14959 false true Reference 70713025 /api/reference/70713025 5. Butler 2024: Accelerometer vs. other activity measures in heart failure with preserved ejection fraction: The VITALITY-HFpEF trial., ESC Heart Fail., 11, p. 293, DOI: 10.1002/ehf2.14572 5 10.1002/ehf2.14572 false true Reference 70713026 /api/reference/70713026 6. Augstein 2025: Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction., ESC Heart Fail., 12, p. 1474, DOI: 10.1002/ehf2.15111 6 10.1002/ehf2.15111 false true Reference 70713027 /api/reference/70713027 7. Cao 2023: Comparison of liver fibrosis scores for predicting mortality and morbidity in heart failure with preserved ejection fraction., ESC Heart Fail., 10, p. 1771, DOI: 10.1002/ehf2.14336 7 10.1002/ehf2.14336 false true Reference 70713028 /api/reference/70713028 8. Chaumont 2023: Is excessive ventricular irregularity predictive of rehospitalization in patients with permanent AF and HFpEF?., ESC Heart Fail., 10, p. 2120, DOI: 10.1002/ehf2.14349 8 10.1002/ehf2.14349 false true Reference 70713029 /api/reference/70713029 9. Choy 2023: Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction., ESC Heart Fail., 10, p. 1214, DOI: 10.1002/ehf2.14225 9 10.1002/ehf2.14225 false true Reference 70713030 /api/reference/70713030 10. Cimino 2024: Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists., ESC Heart Fail., 11, p. 649, DOI: 10.1002/ehf2.14560 10 10.1002/ehf2.14560 false true Reference 70713031 /api/reference/70713031 11. Crum 2024: Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 1698, DOI: 10.1002/ehf2.14739 11 10.1002/ehf2.14739 false true Reference 70713032 /api/reference/70713032 12. Laborante 2024: Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: A meta-analysis., ESC Heart Fail., 11, p. 2063, DOI: 10.1002/ehf2.14626 12 10.1002/ehf2.14626 false true Reference 70713033 /api/reference/70713033 13. Schroen 2025: Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities., ESC Heart Fail., 12, p. 1013, DOI: 10.1002/ehf2.15090 13 10.1002/ehf2.15090 false true Reference 70713034 /api/reference/70713034 14. Erhardsson 2023: Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction., ESC Heart Fail., 10, p. 3729, DOI: 10.1002/ehf2.14569 14 10.1002/ehf2.14569 false true Reference 70713035 /api/reference/70713035 15. Fazzini 2024: Long-term outcomes of phenoclusters in preclinical heart failure with preserved and mildly reduced ejection fraction., ESC Heart Fail., 11, p. 3350, DOI: 10.1002/ehf2.14913 15 10.1002/ehf2.14913 false true Reference 70713036 /api/reference/70713036 16. Gajewski 2025: The Critical Role of Comorbidities in Managing Heart Failure with Preserved Ejection Fraction (HFpEF)., ESC Heart Fail., 12, p. 1541, DOI: 10.1002/ehf2.15169 16 10.1002/ehf2.15169 false true Reference 70713037 /api/reference/70713037 17. Gao 2024: Immune cell profiling of the ICAM1 p.K56M heart failure with preserved ejection fraction risk variant., ESC Heart Fail., 11, p. 4427, DOI: 10.1002/ehf2.14983 17 10.1002/ehf2.14983 false true Reference 70713038 /api/reference/70713038 18. Gao 2025: Electrocardiograph analysis for risk assessment of heart failure with preserved ejection fraction: A deep learning model., ESC Heart Fail., 12, p. 631, DOI: 10.1002/ehf2.15120 18 10.1002/ehf2.15120 false true Reference 70713039 /api/reference/70713039 19. Hamatani 2025: Importance of non-cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction., ESC Heart Fail., 12, p. 389, DOI: 10.1002/ehf2.15093 19 10.1002/ehf2.15093 false true Reference 70713040 /api/reference/70713040 20. He 2024: Identification of molecular signatures in epicardial adipose tissue in heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 2510, DOI: 10.1002/ehf2.14748 20 10.1002/ehf2.14748 false true Reference 70713041 /api/reference/70713041 21. Einarsson 2025: Diagnostic and therapeutic practice for HFpEF across continents and regions: An international survey., ESC Heart Fail., 12, p. 487, DOI: 10.1002/ehf2.15084 21 10.1002/ehf2.15084 false true Reference 70713042 /api/reference/70713042 22. Jovanovic 2024: An altered plasma lipidome–phenome network characterizes heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 1553, DOI: 10.1002/ehf2.14654 22 10.1002/ehf2.14654 false true Reference 70713043 /api/reference/70713043 23. Kitao 2024: Verification of haemoglobin level to prevent worsening of prognosis in heart failure with preserved ejection fraction patients from the PURSUIT-HFpEF registry., ESC Heart Fail., 11, p. 3299, DOI: 10.1002/ehf2.14927 23 10.1002/ehf2.14927 false true Reference 70713044 /api/reference/70713044 24. Kosmala 2024: Do we really need a heart failure with preserved ejection fraction-specific risk stratification strategy?., ESC Heart Fail., 11, p. 1819, DOI: 10.1002/ehf2.14921 24 10.1002/ehf2.14921 false true Reference 70713045 /api/reference/70713045 25. Kyodo 2023: Heart failure with preserved ejection fraction phenogroup classification using machine learning., ESC Heart Fail., 10, p. 2019, DOI: 10.1002/ehf2.14368 25 10.1002/ehf2.14368 false true Reference 70713046 /api/reference/70713046 26. Lanzarone 2023: Haemodynamic validation of the three-step HFA-PEFF algorithm to diagnose heart failure with preserved ejection fraction., ESC Heart Fail., 10, p. 2588, DOI: 10.1002/ehf2.14436 26 10.1002/ehf2.14436 false true Reference 70713047 /api/reference/70713047 27. Leonidou 2023: A case report of a patient with heart failure with preserved ejection fraction presented as dysphagia., ESC Heart Fail., 10, p. 2707, DOI: 10.1002/ehf2.14415 27 10.1002/ehf2.14415 false true Reference 70713048 /api/reference/70713048 28. Li 2023: Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: A meta-analysis., ESC Heart Fail., 10, p. 2225, DOI: 10.1002/ehf2.14421 28 10.1002/ehf2.14421 false true Reference 70713049 /api/reference/70713049 29. Li 2024: Body mass index, frailty, and outcomes in heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 709, DOI: 10.1002/ehf2.14595 29 10.1002/ehf2.14595 false true Reference 70713050 /api/reference/70713050 30. Li 2025: Real world experience in effect of torsemide vs. furosemide after discharge in patients with HFpEF., ESC Heart Fail., 12, p. 71, DOI: 10.1002/ehf2.15071 30 10.1002/ehf2.15071 false true Reference 70713051 /api/reference/70713051 31. Liu 2024: Impact of heart rate changes during hospitalization on outcome in heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 2901, DOI: 10.1002/ehf2.14721 31 10.1002/ehf2.14721 false true Reference 70713052 /api/reference/70713052 32. Meng 2023: Prevalence and prognosis of frailty in older patients with stage B heart failure with preserved ejection fraction., ESC Heart Fail., 10, p. 1133, DOI: 10.1002/ehf2.14274 32 10.1002/ehf2.14274 false true Reference 70713053 /api/reference/70713053 33. Meng 2025: Prognosis of early-stage HFpEF in the community-dwelling elderly: The Northern Shanghai Study., ESC Heart Fail., 12, p. 229, DOI: 10.1002/ehf2.15060 33 10.1002/ehf2.15060 false true Reference 70713054 /api/reference/70713054 34. Menghoum 2024: Carbohydrate antigen 125: A useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 1493, DOI: 10.1002/ehf2.14699 34 10.1002/ehf2.14699 false true Reference 70713055 /api/reference/70713055 35. Mourmans 2025: Prognostic value of hypoxaemic burden from overnight oximetry in heart failure with preserved ejection fraction., ESC Heart Fail., 12, p. 622, DOI: 10.1002/ehf2.15116 35 10.1002/ehf2.15116 false true Reference 70713056 /api/reference/70713056 36. Wolsk 2024: Hyperlactataemia is a marker of reduced exercise capacity in heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 2557, DOI: 10.1002/ehf2.14794 36 10.1002/ehf2.14794 false true Reference 70713057 /api/reference/70713057 37. Nishihara 2023: Association of perivascular fat attenuation on computed tomography and heart failure with preserved ejection fraction., ESC Heart Fail., 10, p. 2447, DOI: 10.1002/ehf2.14419 37 10.1002/ehf2.14419 false true Reference 70713058 /api/reference/70713058 38. Otaki 2023: Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease., ESC Heart Fail., 10, p. 2458, DOI: 10.1002/ehf2.14378 38 10.1002/ehf2.14378 false true Reference 70713059 /api/reference/70713059 39. Shahim 2024: Rates and predictors of cardiovascular and non-cardiovascular outcomes in heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 3572, DOI: 10.1002/ehf2.14928 39 10.1002/ehf2.14928 false true Reference 70713060 /api/reference/70713060 40. Shahim 2023: Long-term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non-cardiac mortality., ESC Heart Fail., 10, p. 1835, DOI: 10.1002/ehf2.14302 40 10.1002/ehf2.14302 false true Reference 70713061 /api/reference/70713061 41. Shiraki 2024: Cardiac sympathetic nerve activity trends after renal denervation in heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 2426, DOI: 10.1002/ehf2.14770 41 10.1002/ehf2.14770 false true Reference 70713062 /api/reference/70713062 42. Tamaki 2024: Relationship of interleukin-16 with different phenogroups in acute heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 2354, DOI: 10.1002/ehf2.14808 42 10.1002/ehf2.14808 false true Reference 70713063 /api/reference/70713063 43. Geurkink 2023: Trimetazidine in heart failure with preserved ejection fraction: A randomized controlled cross-over trial., ESC Heart Fail., 10, p. 2998, DOI: 10.1002/ehf2.14418 43 10.1002/ehf2.14418 false true Reference 70713064 /api/reference/70713064 44. Vernooij 2024: Association of mild kidney dysfunction with diastolic dysfunction and heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 315, DOI: 10.1002/ehf2.14511 44 10.1002/ehf2.14511 false true Reference 70713065 /api/reference/70713065 45. Wang 2024: Systematic review and meta-analysis to predict mortality in heart failure with preserved ejection fraction: Development and validation of the HF-DANAS score., ESC Heart Fail., 11, p. 4104, DOI: 10.1002/ehf2.15008 45 10.1002/ehf2.15008 false true Reference 70713066 /api/reference/70713066 46. Wang 2024: Recurrent heart failure hospitalizations in heart failure with preserved ejection fraction: An analysis of TOPCAT trial., ESC Heart Fail., 11, p. 475, DOI: 10.1002/ehf2.14570 46 10.1002/ehf2.14570 false true Reference 70713067 /api/reference/70713067 47. Wattanachayakul 2025: Invasive haemodynamic assessment in heart failure with preserved ejection fraction., ESC Heart Fail., 12, p. 1558, DOI: 10.1002/ehf2.15163 47 10.1002/ehf2.15163 false true Reference 70713068 /api/reference/70713068 48. Weerts 2023: Webtool to enhance the accuracy of diagnostic algorithms for HFpEF: A prospective cross-over study., ESC Heart Fail., 10, p. 3493, DOI: 10.1002/ehf2.14525 48 10.1002/ehf2.14525 false true Reference 70713069 /api/reference/70713069 49. Weerts 2025: Inter-atrial block as a predictor of adverse outcomes in patients with HFpEF., ESC Heart Fail., 12, p. 2287, DOI: 10.1002/ehf2.15179 49 10.1002/ehf2.15179 false true Reference 70713070 /api/reference/70713070 50. Wu 2024: Advances in device-based treatment of heart failure with preserved ejection fraction: Evidence from clinical trials., ESC Heart Fail., 11, p. 13, DOI: 10.1002/ehf2.14562 50 10.1002/ehf2.14562 false true Reference 70713071 /api/reference/70713071 51. Yamanaka 2024: Age-stratified profiles and outcomes of patients with heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 2223, DOI: 10.1002/ehf2.14798 51 10.1002/ehf2.14798 false true Reference 70713072 /api/reference/70713072 52. Yano 2024: Low-density lipoprotein cholesterol, erythrocyte, and platelet in heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 1758, DOI: 10.1002/ehf2.14734 52 10.1002/ehf2.14734 false true Reference 70713073 /api/reference/70713073 53. Yu 2023: Heart failure with preserved ejection fraction in haemodialysis patients: Prevalence, diagnosis, risk factors, prognosis., ESC Heart Fail., 10, p. 2816, DOI: 10.1002/ehf2.14447 53 10.1002/ehf2.14447 false true Reference 70713074 /api/reference/70713074 54. Zheng 2024: Prediction of 90 day readmission in heart failure with preserved ejection fraction by interpretable machine learning., ESC Heart Fail., 11, p. 4267, DOI: 10.1002/ehf2.15033 54 10.1002/ehf2.15033 false true Reference 70713075 /api/reference/70713075 55. Mrak 2024: Complexities of treating co-morbidities in heart failure with preserved ejection fraction., ESC Heart Fail., 11, p. 3425, DOI: 10.1002/ehf2.14897 55 10.1002/ehf2.14897 false true Reference 70713076 /api/reference/70713076 56. Sequeira 2024: Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure with Preserved Ejection Fraction., Circ Heart Fail., 17, p. e011833 56 false true Reference 70713077 /api/reference/70713077 57. Alogna 2023: Interleukin-6 in Patients with Heart Failure and Preserved Ejection Fraction., JACC Heart Fail., 11, p. 1549, DOI: 10.1016/j.jchf.2023.06.031 57 10.1016/j.jchf.2023.06.031 false true Reference 70713078 /api/reference/70713078 58. Azzo 2024: Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure with Preserved Ejection Fraction., Circ. Heart Fail., 17, p. e011146, DOI: 10.1161/CIRCHEARTFAILURE.123.011146 58 10.1161/CIRCHEARTFAILURE.123.011146 false true Reference 70713079 /api/reference/70713079 59. Badrov 2025: Sympathetic Response to 1-Leg Cycling Exercise Predicts Exercise Capacity in Patients with Heart Failure with Preserved Ejection Fraction., Circ. Heart Fail., 18, p. e011962, DOI: 10.1161/CIRCHEARTFAILURE.124.011962 59 10.1161/CIRCHEARTFAILURE.124.011962 false true Reference 70713080 /api/reference/70713080 60. Brubaker 2023: A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure with Preserved Ejection Fraction., Circ. Heart Fail., 16, p. 116 60 false true Reference 70713081 /api/reference/70713081 61. Chieng 2023: Atrial Fibrillation Ablation for Heart Failure with Preserved Ejection Fraction., JACC Heart Fail., 11, p. 646, DOI: 10.1016/j.jchf.2023.01.008 61 10.1016/j.jchf.2023.01.008 false true Reference 70713082 /api/reference/70713082 62. Defilippi 2024: Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure with Preserved Ejection Fraction: Insights From VITALITY-HFpEF., Circ Heart Fail., 17, p. e011792, DOI: 10.1161/CIRCHEARTFAILURE.124.011792 62 10.1161/CIRCHEARTFAILURE.124.011792 false true Reference 70713083 /api/reference/70713083 63. Desai 2023: How to Manage Heart Failure with Preserved Ejection Fraction., JACC Heart Fail., 11, p. 619, DOI: 10.1016/j.jchf.2023.03.011 63 10.1016/j.jchf.2023.03.011 false true Reference 70713084 /api/reference/70713084 64. Dhont 2024: Mitral regurgitation in heart failure with preserved ejection fraction: The interplay of valve, ventricle, and atrium., Eur. J. Heart Fail., 26, p. 974, DOI: 10.1002/ejhf.3231 64 10.1002/ejhf.3231 false true Reference 70713085 /api/reference/70713085 65. Fudim 2024: Discrepancy in the Diagnosis of Heart Failure with Preserved Ejection Fraction Between Supine Versus Upright Exercise Hemodynamic Testing., Circ. Heart Fail., 17, p. e012020, DOI: 10.1161/CIRCHEARTFAILURE.124.012020 65 10.1161/CIRCHEARTFAILURE.124.012020 false true Reference 70713086 /api/reference/70713086 66. Goudot 2024: Heart Failure with Preserved Ejection Fraction: From a Vascular Perspective., Circ. Heart Fail., 17, p. e012187, DOI: 10.1161/CIRCHEARTFAILURE.124.012187 66 10.1161/CIRCHEARTFAILURE.124.012187 false true Reference 70713087 /api/reference/70713087 67. Guidetti 2025: Differences in heart failure with preserved ejection fraction management between care providers: An international survey., Eur. J. Heart Fail., 27, p. 198, DOI: 10.1002/ejhf.3416 67 10.1002/ejhf.3416 false true Reference 70713088 /api/reference/70713088 68. Haim 2025: Modeling Heart Failure with Preserved Ejection Fraction Using Human Induced Pluripotent Stem Cell–Derived Cardiac Organoids., Circ. Heart Fail., 18, p. e011690, DOI: 10.1161/CIRCHEARTFAILURE.124.011690 68 10.1161/CIRCHEARTFAILURE.124.011690 false true Reference 70713089 /api/reference/70713089 69. Harada 2024: Cardiac function, haemodynamics, and valve competence with exercise in patients with heart failure with preserved ejection fraction and mild to moderate secondary mitral regurgitation., Eur. J. Heart Fail., 26, p. 1616, DOI: 10.1002/ejhf.3322 69 10.1002/ejhf.3322 false true Reference 70713090 /api/reference/70713090 70. Horiuchi 2023: Prevalence, characteristics and cardiovascular and non-cardiovascular outcomes in patients with heart failure with supra-normal ejection fraction: Insight from the JROADHF study., Eur. J. Heart Fail., 25, p. 989, DOI: 10.1002/ejhf.2895 70 10.1002/ejhf.2895 false true Reference 70713091 /api/reference/70713091 71. Kitzman 2024: A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial., Eur. J. Heart Fail., 26, p. 2013 71 false true Reference 70713092 /api/reference/70713092 72. Koleini 2024: Landscape of glycolytic metabolites and their regulating proteins in myocardium from human heart failure with preserved ejection fraction., Eur. J. Heart Fail., 26, p. 1941 72 false true Reference 70713093 /api/reference/70713093 73. Kondo 2024: Low Natriuretic Peptide Levels and Outcomes in Patients with Heart Failure and Preserved Ejection Fraction., JACC Heart Fail., 12, p. 1442, DOI: 10.1016/j.jchf.2024.04.027 73 10.1016/j.jchf.2024.04.027 false true Reference 70713094 /api/reference/70713094 74. Kondo 2023: Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation., Circ. Heart Fail., 16, p. e010377, DOI: 10.1161/CIRCHEARTFAILURE.122.010377 74 10.1161/CIRCHEARTFAILURE.122.010377 false true Reference 70713095 /api/reference/70713095 75. Kosyakovsky 2024: Uncovering Unrecognized Heart Failure with Preserved Ejection Fraction Among Individuals with Obesity and Dyspnea., Circ. Heart Fail., 17, p. e011366, DOI: 10.1161/CIRCHEARTFAILURE.123.011366 75 10.1161/CIRCHEARTFAILURE.123.011366 false true Reference 70713096 /api/reference/70713096 76. Larson 2024: Clinical phenogroup diversity and multiplicity: Impact on mechanisms of exercise intolerance in heart failure with preserved ejection fraction., Eur. J. Heart Fail., 26, p. 564, DOI: 10.1002/ejhf.3105 76 10.1002/ejhf.3105 false true Reference 70713097 /api/reference/70713097 77. Lenselink 2024: Incidence and predictors of heart failure with reduced and preserved ejection fraction after ST-elevation myocardial infarction in the contemporary era of early percutaneous coronary intervention., Eur. J. Heart Fail., 26, p. 1142, DOI: 10.1002/ejhf.3225 77 10.1002/ejhf.3225 false true Reference 70713098 /api/reference/70713098 78. Lund 2024: The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design., Eur. J. Heart Fail., 26, p. 2453, DOI: 10.1002/ejhf.3453 78 10.1002/ejhf.3453 false true Reference 70713099 /api/reference/70713099 79. Ostrominski 2025: Efficacy and Safety of Finerenone in Heart Failure with Preserved Ejection Fraction., JACC Heart Fail., 13, p. 102497, DOI: 10.1016/j.jchf.2025.03.041 79 10.1016/j.jchf.2025.03.041 false true Reference 70713100 /api/reference/70713100 80. Packer 2025: The Adipokine Hypothesis of Heart Failure with a Preserved Ejection Fraction., JACC, 86, p. 1269, DOI: 10.1016/j.jacc.2025.06.055 80 10.1016/j.jacc.2025.06.055 false true Reference 70713101 /api/reference/70713101 81. Parwani 2024: Catheter-based ablation to improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction: Rationale and design of the CABA-HFPEF-DZHK27 trial., Eur. J. Heart Fail., 26, p. 2203, DOI: 10.1002/ejhf.3373 81 10.1002/ejhf.3373 false true Reference 70713102 /api/reference/70713102 82. Rommel 2023: Modulation of Pulsatile Left Ventricular Afterload by Renal Denervation in Heart Failure with Preserved Ejection Fraction., Circ. Heart Fail., 16, p. e010543, DOI: 10.1161/CIRCHEARTFAILURE.123.010543 82 10.1161/CIRCHEARTFAILURE.123.010543 false true Reference 70713103 /api/reference/70713103 83. Saito 2023: Disproportionate exercise-induced pulmonary hypertension in relation to cardiac output in heart failure with preserved ejection fraction: A non-invasive echocardiographic study., Eur. J. Heart Fail., 25, p. 792, DOI: 10.1002/ejhf.2821 83 10.1002/ejhf.2821 false true Reference 70713104 /api/reference/70713104 84. Saw 2025: Musclin Counteracts Skeletal Muscle Dysfunction and Exercise Intolerance in Heart Failure with Preserved Ejection Fraction., Circ. Heart Fail., 18, p. e012350, DOI: 10.1161/CIRCHEARTFAILURE.124.012350 84 10.1161/CIRCHEARTFAILURE.124.012350 false true Reference 70713105 /api/reference/70713105 85. Schuster 2023: Concomitant latent pulmonary vascular disease leads to impaired global cardiac performance in heart failure with preserved ejection fraction., Eur. J. Heart Fail., 25, p. 322, DOI: 10.1002/ejhf.2781 85 10.1002/ejhf.2781 false true Reference 70713106 /api/reference/70713106 86. Skow 2024: Identifying the Mechanisms of a Peripherally Limited Exercise Phenotype in Patients with Heart Failure with Preserved Ejection Fraction., Circ. Heart Fail., 17, p. e011693, DOI: 10.1161/CIRCHEARTFAILURE.123.011693 86 10.1161/CIRCHEARTFAILURE.123.011693 false true Reference 70713107 /api/reference/70713107 87. Tang 2024: Nonpharmacological Approaches to Managing Heart Failure with Preserved Ejection Fraction., Circ. Heart Fail., 17, p. e011269, DOI: 10.1161/CIRCHEARTFAILURE.123.011269 87 10.1161/CIRCHEARTFAILURE.123.011269 false true Reference 70713108 /api/reference/70713108 88. Martin 2024: Impact of Digital Health Technology on Quality of Life in Patients with Heart Failure., JACC Heart Fail., 12, p. 336, DOI: 10.1016/j.jchf.2023.09.022 88 10.1016/j.jchf.2023.09.022 false true Reference 70713109 /api/reference/70713109 89. Wu 2024: Artificial intelligence methods for improved detection of undiagnosed heart failure with preserved ejection fraction., Eur. J. Heart Fail., 26, p. 302, DOI: 10.1002/ejhf.3115 89 10.1002/ejhf.3115 false true Reference 70713110 /api/reference/70713110 90. Ye 2023: Left Ventricular Gene Expression in Heart Failure with Preserved Ejection Fraction—Profibrotic and Proinflammatory Pathways and Genes., Circ. Heart Fail., 16, p. e010395, DOI: 10.1161/CIRCHEARTFAILURE.123.010395 90 10.1161/CIRCHEARTFAILURE.123.010395 false true Reference 70713111 /api/reference/70713111 91. Kramer 2025: Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure., J. Am. Coll. Cardiol., 85, p. 699, DOI: 10.1016/j.jacc.2024.11.001 91 10.1016/j.jacc.2024.11.001 false true Reference 70713112 /api/reference/70713112 92. Kosiborod 2024: Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: A pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials., Lancet, 404, p. 949, DOI: 10.1016/S0140-6736(24)01643-X 92 10.1016/S0140-6736(24)01643-X false true Reference 70713113 /api/reference/70713113 93. Kosiborod 2023: Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients with Obesity HFpEF Phenotype., JACC Heart Fail., 11, p. 1000, DOI: 10.1016/j.jchf.2023.05.010 93 10.1016/j.jchf.2023.05.010 false true Reference 70713114 /api/reference/70713114 94. Kosiborod 2024: Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes., N. Engl. J. Med., 390, p. 1394, DOI: 10.1056/NEJMoa2313917 94 10.1056/NEJMoa2313917 false true Reference 70713115 /api/reference/70713115 95. Packer 2025: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity., N. Engl. J. Med., 392, p. 427, DOI: 10.1056/NEJMoa2410027 95 10.1056/NEJMoa2410027 false true Reference 70713116 /api/reference/70713116 96. Deanfield 2024: Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: A prespecified analysis of the SELECT trial., Lancet, 404, p. 773, DOI: 10.1016/S0140-6736(24)01498-3 96 10.1016/S0140-6736(24)01498-3 false true Reference 70713117 /api/reference/70713117 97. Savarese 2025: Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC., Eur. J. Heart Fail., 27, p. 1273, DOI: 10.1002/ejhf.3676 97 10.1002/ejhf.3676 false true Reference 70713118 /api/reference/70713118 98. Vest 2024: Obesity and Weight Loss Strategies for Patients with Heart Failure., JACC Heart Fail., 12, p. 1509, DOI: 10.1016/j.jchf.2024.06.006 98 10.1016/j.jchf.2024.06.006 false true Reference 70713119 /api/reference/70713119 99. Neuen 2024: Cardiovascular, Kidney, and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis., Circulation, 150, p. 1781, DOI: 10.1161/CIRCULATIONAHA.124.071689 99 10.1161/CIRCULATIONAHA.124.071689 false true Reference 70713120 /api/reference/70713120 100. Abdin 2024: Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER., Eur. J. Heart Fail., 26, p. 1952 100 false true Reference 70713121 /api/reference/70713121 101. Anker 2021: Empagliflozin in Heart Failure with a Preserved Ejection Fraction., N. Engl. J. Med., 385, p. 1451, DOI: 10.1056/NEJMoa2107038 101 10.1056/NEJMoa2107038 false true Reference 70713122 /api/reference/70713122 102. Arnold 2023: Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction., JACC Heart Fail., 11, p. 893, DOI: 10.1016/j.jchf.2023.03.017 102 10.1016/j.jchf.2023.03.017 false true Reference 70713123 /api/reference/70713123 103. Baigent 2022: Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials., Lancet, 400, p. 1788, DOI: 10.1016/S0140-6736(22)02074-8 103 10.1016/S0140-6736(22)02074-8 false true Reference 70713124 /api/reference/70713124 104. Bhatt 2023: Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial., Eur. J. Heart Fail., 25, p. 2177, DOI: 10.1002/ejhf.3043 104 10.1002/ejhf.3043 false true Reference 70713125 /api/reference/70713125 105. Butt 2023: Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER., Eur. J. Heart Fail., 25, p. 2078, DOI: 10.1002/ejhf.3000 105 10.1002/ejhf.3000 false true Reference 70713126 /api/reference/70713126 106. Chimura 2024: Finerenone Improves Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF., Circ. Heart Fail., 17, p. e012437, DOI: 10.1161/CIRCHEARTFAILURE.124.012437 106 10.1161/CIRCHEARTFAILURE.124.012437 false true Reference 70713127 /api/reference/70713127 107. Ferreira 2024: Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis., Eur. J. Heart Fail., 26, p. 952, DOI: 10.1002/ejhf.3180 107 10.1002/ejhf.3180 false true Reference 70713128 /api/reference/70713128 108. Fioretti 2025: Left Atrial-to-Coronary Sinus Shunting in Heart Failure with Mildly Reduced or Preserved Ejection Fraction., JACC Heart Fail., 13, p. 987, DOI: 10.1016/j.jchf.2025.02.003 108 10.1016/j.jchf.2025.02.003 false true Reference 70713129 /api/reference/70713129 109. Heidenreich 2022: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines., Circulation, 145, p. E895 109 false true Reference 70713130 /api/reference/70713130 110. Kerwagen 2023: Remote patient management of heart failure across the ejection fraction spectrum: A pre-specified analysis of the TIM-HF2 trial., Eur. J. Heart Fail., 25, p. 1671, DOI: 10.1002/ejhf.2948 110 10.1002/ejhf.2948 false true Reference 70713131 /api/reference/70713131 111. Keshvani 2023: Sex differences in long-term outcomes following acute heart failure hospitalization: Findings from the Get with The Guidelines-Heart Failure registry., Eur. J. Heart Fail., 25, p. 1544, DOI: 10.1002/ejhf.3003 111 10.1002/ejhf.3003 false true Reference 70713132 /api/reference/70713132 112. Lund 2024: Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction—The ESC EORP Heart Failure III Registry., Eur. J. Heart Fail., 26, p. 2487, DOI: 10.1002/ejhf.3445 112 10.1002/ejhf.3445 false true Reference 70713133 /api/reference/70713133 113. Lund 2023: Rationale and design of ENDEAVOR: A sequential phase 2b–3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction., Eur. J. Heart Fail., 25, p. 1696, DOI: 10.1002/ejhf.2977 113 10.1002/ejhf.2977 false true Reference 70713134 /api/reference/70713134 114. Matsumoto 2025: Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction., Eur. J. Heart Fail., 27, p. 124, DOI: 10.1002/ejhf.3383 114 10.1002/ejhf.3383 false true Reference 70713135 /api/reference/70713135 115. Matsumoto 2023: Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction., Eur. J. Heart Fail., 25, p. 2202, DOI: 10.1002/ejhf.3044 115 10.1002/ejhf.3044 false true Reference 70713136 /api/reference/70713136 116. Schupp 2024: Prevalence and prognosis of aortic valve diseases in patients hospitalized with heart failure with mildly reduced ejection fraction., Eur. J. Heart Fail., 26, p. 1832, DOI: 10.1002/ejhf.3337 116 10.1002/ejhf.3337 false true Reference 70713137 /api/reference/70713137 117. Selvaraj 2023: Blood Pressure and Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction., JACC Heart Fail., 11, p. 76, DOI: 10.1016/j.jchf.2022.09.002 117 10.1016/j.jchf.2022.09.002 false true Reference 70713138 /api/reference/70713138 118. Settergren 2024: Cause-specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry., Eur. J. Heart Fail., 26, p. 1150, DOI: 10.1002/ejhf.3230 118 10.1002/ejhf.3230 false true Reference 70713139 /api/reference/70713139 119. Shahim 2023: Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry., Eur. J. Heart Fail., 25, p. 1049, DOI: 10.1002/ejhf.2908 119 10.1002/ejhf.2908 false true Reference 70713140 /api/reference/70713140 120. Solomon 2022: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction., N. Engl. J. Med., 387, p. 1089, DOI: 10.1056/NEJMoa2206286 120 10.1056/NEJMoa2206286 false true Reference 70713141 /api/reference/70713141 121. Solomon 2024: Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction., N. Engl. J. Med., 391, p. 1475, DOI: 10.1056/NEJMoa2407107 121 10.1056/NEJMoa2407107 false true Reference 70713142 /api/reference/70713142 122. Solomon 2024: Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trial., Eur. J. Heart Fail., 26, p. 1334, DOI: 10.1002/ejhf.3266 122 10.1002/ejhf.3266 false true Reference 70713143 /api/reference/70713143 123. Urey 2024: Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1-year results., Eur. J. Heart Fail., 26, p. 1065, DOI: 10.1002/ejhf.3241 123 10.1002/ejhf.3241 false true Reference 70713144 /api/reference/70713144 124. Yang 2024: Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction., Eur. J. Heart Fail., 26, p. 1788, DOI: 10.1002/ejhf.3352 124 10.1002/ejhf.3352 false true Reference 70713145 /api/reference/70713145 125. Yang 2024: Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction., Eur. J. Heart Fail., 26, p. 1524, DOI: 10.1002/ejhf.3263 125 10.1002/ejhf.3263 false true Reference 70713146 /api/reference/70713146 126. Zannad 2020: SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials., Lancet, 396, p. 819, DOI: 10.1016/S0140-6736(20)31824-9 126 10.1016/S0140-6736(20)31824-9 false true Reference 70713147 /api/reference/70713147 127. Arfsten 2024: Excess renin is attributed to the combination of forward and backward failure in HFrEF., ESC Heart Fail., 11, p. 1748, DOI: 10.1002/ehf2.14731 127 10.1002/ehf2.14731 false true Reference 70713148 /api/reference/70713148 128. Bergh 2024: Estimating the clinical and budgetary impact of using angiotensin receptor neprilysin inhibitor as first line therapy in patients with HFrEF., ESC Heart Fail., 11, p. 1153, DOI: 10.1002/ehf2.14551 128 10.1002/ehf2.14551 false true Reference 70713149 /api/reference/70713149 129. Blanco 2023: Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: A single-centre experience., ESC Heart Fail., 10, p. 3373, DOI: 10.1002/ehf2.14508 129 10.1002/ehf2.14508 false true Reference 70713150 /api/reference/70713150 130. Cho 2025: Angiotensin receptor-neprilysin inhibitor adherence and outcomes in heart failure with reduced ejection fraction., ESC Heart Fail., 12, p. 603, DOI: 10.1002/ehf2.15117 130 10.1002/ehf2.15117 false true Reference 70713151 /api/reference/70713151 131. Christensen 2024: Circulating 3-hydroxy butyrate predicts mortality in patients with chronic heart failure with reduced ejection fraction., ESC Heart Fail., 11, p. 837, DOI: 10.1002/ehf2.14476 131 10.1002/ehf2.14476 false true Reference 70713152 /api/reference/70713152 132. Greene 2024: Treatment patterns of patients with worsening heart failure with reduced ejection fraction., ESC Heart Fail., 11, p. 1932, DOI: 10.1002/ehf2.14805 132 10.1002/ehf2.14805 false true Reference 70713153 /api/reference/70713153 133. Hammer 2023: Vericiguat: A fifth cornerstone in the treatment of heart failure with reduced ejection fraction?., ESC Heart Fail., 10, p. 3735, DOI: 10.1002/ehf2.14549 133 10.1002/ehf2.14549 false true Reference 70713154 /api/reference/70713154 134. Ergin 2023: Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction., ESC Heart Fail., 10, p. 3677, DOI: 10.1002/ehf2.14559 134 10.1002/ehf2.14559 false true Reference 70713155 /api/reference/70713155 135. Lauder 2023: Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction., ESC Heart Fail., 10, p. 2559, DOI: 10.1002/ehf2.14384 135 10.1002/ehf2.14384 false true Reference 70713156 /api/reference/70713156 136. Lim 2024: Eligibility of Asian and European registry patients for phase III trials in heart failure with reduced ejection fraction., ESC Heart Fail., 11, p. 3559, DOI: 10.1002/ehf2.14751 136 10.1002/ehf2.14751 false true Reference 70713157 /api/reference/70713157 137. Mathew 2023: Impact of sleep apnoea on 30 day hospital readmission rate and cost in heart failure with reduced ejection fraction., ESC Heart Fail., 10, p. 2534, DOI: 10.1002/ehf2.14430 137 10.1002/ehf2.14430 false true Reference 70713158 /api/reference/70713158 138. 2023: Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: Systematic review., ESC Heart Fail., 10, p. 2760, DOI: 10.1002/ehf2.14473 138 10.1002/ehf2.14473 false true Reference 70713159 /api/reference/70713159 139. Monzo 2024: Pressure overload is associated with right ventricular dyssynchrony in heart failure with reduced ejection fraction., ESC Heart Fail., 11, p. 1097, DOI: 10.1002/ehf2.14682 139 10.1002/ehf2.14682 false true Reference 70713160 /api/reference/70713160 140. Narducci 2024: Cost–utility of cardiac contractility modulation in patients with heart failure with reduced ejection fraction in Italy., ESC Heart Fail., 11, p. 229, DOI: 10.1002/ehf2.14538 140 10.1002/ehf2.14538 false true Reference 70713161 /api/reference/70713161 141. Riveland 2024: Exercise training and high-sensitivity cardiac troponin-I in patients with heart failure with reduced ejection fraction., ESC Heart Fail., 11, p. 1121, DOI: 10.1002/ehf2.14674 141 10.1002/ehf2.14674 false true Reference 70713162 /api/reference/70713162 142. Sayour 2025: Comparison of mouse models of heart failure with reduced ejection fraction., ESC Heart Fail., 12, p. 87, DOI: 10.1002/ehf2.15031 142 10.1002/ehf2.15031 false true Reference 70713163 /api/reference/70713163 143. Sherwood 2024: Depressive symptoms are associated with clinical outcomes in heart failure with reduced ejection fraction., ESC Heart Fail., 11, p. 2627, DOI: 10.1002/ehf2.14758 143 10.1002/ehf2.14758 false true Reference 70713164 /api/reference/70713164 144. Solymossi 2024: Incidence and predictors of heart failure with improved ejection fraction category in a HFrEF patient population., ESC Heart Fail., 11, p. 783, DOI: 10.1002/ehf2.14619 144 10.1002/ehf2.14619 false true Reference 70713165 /api/reference/70713165 145. Sun 2024: S2I2N0–3 score predicts short- and long-term mortality and morbidity in HFrEF: A post-hoc analysis of the GUIDE-IT trial., ESC Heart Fail., 11, p. 1422, DOI: 10.1002/ehf2.14689 145 10.1002/ehf2.14689 false true Reference 70713166 /api/reference/70713166 146. Suzuki 2024: Evaluating haemodynamic changes: Vericiguat in patients with heart failure with reduced ejection fraction., ESC Heart Fail., 11, p. 2451, DOI: 10.1002/ehf2.14802 146 10.1002/ehf2.14802 false true Reference 70713167 /api/reference/70713167 147. Tochiya 2023: Diabetic microvascular complications predicts non-heart failure with reduced ejection fraction in type 2 diabetes., ESC Heart Fail., 10, p. 1158, DOI: 10.1002/ehf2.14280 147 10.1002/ehf2.14280 false true Reference 70713168 /api/reference/70713168 148. Verheyen 2024: Prevalence and prognostic impact of bone disease in chronic heart failure with reduced ejection fraction., ESC Heart Fail., 11, p. 1730, DOI: 10.1002/ehf2.14741 148 10.1002/ehf2.14741 false true Reference 70713169 /api/reference/70713169 149. Zhou 2024: Tyrosine to threonine ratio was related to heart failure with reduced or mildly reduced ejection fraction., ESC Heart Fail., 11, p. 1567, DOI: 10.1002/ehf2.14700 149 10.1002/ehf2.14700 false true Reference 70713170 /api/reference/70713170 150. Zhou 2024: Reply to the letter regarding the article ‘The prevalence, predictors, and outcomes of left ventricular thrombus in HFrEF’., ESC Heart Fail., 11, p. 3455, DOI: 10.1002/ehf2.14941 150 10.1002/ehf2.14941 false true Reference 70713171 /api/reference/70713171 151. Curran 2021: Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction., ESC Heart Fail., 8, p. 3168, DOI: 10.1002/ehf2.13424 151 10.1002/ehf2.13424 false true Reference 70713172 /api/reference/70713172 152. Abdin 2024: Neuromodulation interventions in the management of heart failure., Eur. J. Heart Fail., 26, p. 502, DOI: 10.1002/ejhf.3147 152 10.1002/ejhf.3147 false true Reference 70713173 /api/reference/70713173 153. Adamo 2024: Tricuspid Regurgitation and Clinical Outcomes in Heart Failure with Reduced Ejection Fraction., JACC Heart Fail., 12, p. 552, DOI: 10.1016/j.jchf.2023.11.018 153 10.1016/j.jchf.2023.11.018 false true Reference 70713174 /api/reference/70713174 154. Bansal 2024: Risk Factors and Outcomes Associated with Heart Failure with Preserved and Reduced Ejection Fraction in People with Chronic Kidney Disease., Circ. Heart Fail., 17, p. e011173, DOI: 10.1161/CIRCHEARTFAILURE.123.011173 154 10.1161/CIRCHEARTFAILURE.123.011173 false true Reference 70713175 /api/reference/70713175 155. Barat 2023: Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trial., Eur. J. Heart Fail., 25, p. 1256, DOI: 10.1002/ejhf.2886 155 10.1002/ejhf.2886 false true Reference 70713176 /api/reference/70713176 156. Butler 2022: Vericiguat and Health-Related Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction: Insights From the VICTORIA Trial., Circ. Heart Fail., 15, p. e009337, DOI: 10.1161/CIRCHEARTFAILURE.121.009337 156 10.1161/CIRCHEARTFAILURE.121.009337 false true Reference 70713177 /api/reference/70713177 157. Cao 2024: Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry., Eur. J. Heart Fail., 26, p. 2518, DOI: 10.1002/ejhf.3378 157 10.1002/ejhf.3378 false true Reference 70713178 /api/reference/70713178 158. Cappelletto 2023: Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: Data from the Swedish Heart Failure Registry., Eur. J. Heart Fail., 25, p. 698, DOI: 10.1002/ejhf.2795 158 10.1002/ejhf.2795 false true Reference 70713179 /api/reference/70713179 159. Chew 2023: Cost-Effectiveness of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial., Circulation, 148, p. 1087, DOI: 10.1161/CIRCULATIONAHA.122.063602 159 10.1161/CIRCULATIONAHA.122.063602 false true Reference 70713180 /api/reference/70713180 160. Dauw 2024: Sodium loading in ambulatory patients with heart failure with reduced ejection fraction: Mechanistic insights into sodium handling., Eur. J. Heart Fail., 26, p. 616, DOI: 10.1002/ejhf.3131 160 10.1002/ejhf.3131 false true Reference 70713181 /api/reference/70713181 161. Dixit 2023: Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure with Reduced Ejection Fraction., JACC Heart Fail., 11, p. 541, DOI: 10.1016/j.jchf.2023.01.004 161 10.1016/j.jchf.2023.01.004 false true Reference 70713182 /api/reference/70713182 162. Ezekowitz 2023: Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial., Circ. Heart Fail., 16, p. 799, DOI: 10.1161/CIRCHEARTFAILURE.123.010599 162 10.1161/CIRCHEARTFAILURE.123.010599 false true Reference 70713183 /api/reference/70713183 163. Grassi 2024: Baroreceptors as a target of device-based neuromodulation in heart failure: Long-term outcomes., Eur. J. Heart Fail., 26, p. 1062, DOI: 10.1002/ejhf.3258 163 10.1002/ejhf.3258 false true Reference 70713184 /api/reference/70713184 164. Khan 2024: Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status., JACC Heart Fail., 12, p. 1750, DOI: 10.1016/j.jchf.2024.05.007 164 10.1016/j.jchf.2024.05.007 false true Reference 70713185 /api/reference/70713185 165. Khan 2023: Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States., JACC Heart Fail., 11, p. 211, DOI: 10.1016/j.jchf.2022.11.007 165 10.1016/j.jchf.2022.11.007 false true Reference 70713186 /api/reference/70713186 166. Lam 2023: Age, Sex, and Outcomes in Heart Failure with Reduced EF., JACC Heart Fail., 11, p. 1246, DOI: 10.1016/j.jchf.2023.06.020 166 10.1016/j.jchf.2023.06.020 false true Reference 70713187 /api/reference/70713187 167. Monzo, L., Bresso, E., Dickstein, K., Pitt, B., Cleland, J.G., Anker, S.D., Lam, C.S., Mehra, M.R., van Veldhuisen, D.J., and Greenberg, B. (2024). Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction. Eur. J. Heart Fail., ejhf.3547., DOI: 10.1002/ejhf.3547 167 10.1002/ejhf.3547 false true Reference 70713188 /api/reference/70713188 168. Nguyen 2023: Eligibility for vericiguat in a real-world heart failure population according to trial, guideline and label criteria: Data from the Swedish Heart Failure Registry., Eur. J. Heart Fail., 25, p. 1418, DOI: 10.1002/ejhf.2939 168 10.1002/ejhf.2939 false true Reference 70713189 /api/reference/70713189 169. Pieske 2023: Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy., Eur. J. Heart Fail., 25, p. 1012, DOI: 10.1002/ejhf.2836 169 10.1002/ejhf.2836 false true Reference 70713190 /api/reference/70713190 170. Reddy 2025: Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial., Eur. J. Heart Fail., 27, p. 209, DOI: 10.1002/ejhf.3501 170 10.1002/ejhf.3501 false true Reference 70713191 /api/reference/70713191 171. Sears 2024: Long-Term Quality of Life Response Observed in the Baroreflex Activation Therapy for Heart Failure Trial., JACC Heart Fail., 12, p. 2110, DOI: 10.1016/j.jchf.2024.07.013 171 10.1016/j.jchf.2024.07.013 false true Reference 70713192 /api/reference/70713192 172. Swat 2023: Opportunities and Achievement of Medication Initiation Among Inpatients with Heart Failure with Reduced Ejection Fraction., JACC Heart Fail., 11, p. 918, DOI: 10.1016/j.jchf.2023.04.015 172 10.1016/j.jchf.2023.04.015 false true Reference 70713193 /api/reference/70713193 173. Tomasoni 2024: Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry., Eur. J. Heart Fail., 26, p. 327, DOI: 10.1002/ejhf.3081 173 10.1002/ejhf.3081 false true Reference 70713194 /api/reference/70713194 174. Tharshana 2024: Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: A phenomics approach., Eur. J. Heart Fail., 26, p. 841, DOI: 10.1002/ejhf.3156 174 10.1002/ejhf.3156 false true Reference 70713195 /api/reference/70713195 175. Verma 2023: DASH-HF Study: A Pragmatic Quality Improvement Randomized Implementation Trial for Patients with Heart Failure with Reduced Ejection Fraction., Circ. Heart Fail., 16, p. 763, DOI: 10.1161/CIRCHEARTFAILURE.122.010278 175 10.1161/CIRCHEARTFAILURE.122.010278 false true Reference 70713196 /api/reference/70713196 176. Witting 2023: Treatment Differences in Medical Therapy for Heart Failure with Reduced Ejection Fraction Between Sociodemographic Groups., JACC Heart Fail., 11, p. 161, DOI: 10.1016/j.jchf.2022.08.023 176 10.1016/j.jchf.2022.08.023 false true Reference 70713197 /api/reference/70713197 177. Zile 2024: Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long-term outcomes., Eur. J. Heart Fail., 26, p. 1051, DOI: 10.1002/ejhf.3232 177 10.1002/ejhf.3232 false true Reference 70713198 /api/reference/70713198 178. Kittipibul 2025: Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial., ESC Heart Fail., 12, p. 1479, DOI: 10.1002/ehf2.15134 178 10.1002/ehf2.15134 false true Reference 70713199 /api/reference/70713199 179. Jiang 2025: Pulmonary artery pressure trajectories in heart failure patients treated with GLP-1 receptor agonists., ESC Heart Fail., 12, p. 2578, DOI: 10.1002/ehf2.15308 179 10.1002/ehf2.15308 false true Reference 70713200 /api/reference/70713200 180. Krammer 2025: Cardioprotective effects of semaglutide on isolated human ventricular myocardium., Eur. J. Heart Fail., 27, p. 1315, DOI: 10.1002/ejhf.3644 180 10.1002/ejhf.3644 false true Reference 70713201 /api/reference/70713201 181. Neuen 2024: Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared with Conventional Care in Patients with Type 2 Diabetes and Albuminuria., Circulation, 149, p. 450, DOI: 10.1161/CIRCULATIONAHA.123.067584 181 10.1161/CIRCULATIONAHA.123.067584 false true Reference 70713202 /api/reference/70713202 182. Ambrosy 2025: Baseline kidney function and the effects of dapagliflozin on health status in heart failure in DEFINE-HF and PRESERVED-HF., ESC Heart Fail., 12, p. 1676, DOI: 10.1002/ehf2.15184 182 10.1002/ehf2.15184 false true Reference 70713203 /api/reference/70713203 183. Amioka 2025: Long-term efficacy of SGLT2 inhibitors for elderly patients with acute decompensated heart failure: The OASIS-HF study., ESC Heart Fail., 12, p. 447, DOI: 10.1002/ehf2.15088 183 10.1002/ehf2.15088 false true Reference 70713204 /api/reference/70713204 184. Beles 2023: Cardio–renal–metabolic syndrome: Clinical features and dapagliflozin eligibility in a real-world heart failure cohort., ESC Heart Fail., 10, p. 2269, DOI: 10.1002/ehf2.14381 184 10.1002/ehf2.14381 false true Reference 70713205 /api/reference/70713205 185. Bosch 2023: Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure., ESC Heart Fail., 10, p. 1635, DOI: 10.1002/ehf2.14313 185 10.1002/ehf2.14313 false true Reference 70713206 /api/reference/70713206 186. Carberry 2024: Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): Rationale and design., ESC Heart Fail., 11, p. 2001, DOI: 10.1002/ehf2.14830 186 10.1002/ehf2.14830 false true Reference 70713207 /api/reference/70713207 187. Chen 2025: Dapagliflozin alleviates high-fat-induced obesity cardiomyopathy by inhibiting ferroptosis., ESC Heart Fail., 12, p. 1358, DOI: 10.1002/ehf2.15150 187 10.1002/ehf2.15150 false true Reference 70713208 /api/reference/70713208 188. Chen 2023: Indirect comparison of SGLT2 inhibitors in patients with established heart failure: Evidence based on Bayesian methods., ESC Heart Fail., 10, p. 1231, DOI: 10.1002/ehf2.14297 188 10.1002/ehf2.14297 false true Reference 70713209 /api/reference/70713209 189. Clemmer 2023: Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction., ESC Heart Fail., 10, p. 2010, DOI: 10.1002/ehf2.14347 189 10.1002/ehf2.14347 false true Reference 70713210 /api/reference/70713210 190. Ji 2023: The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure., ESC Heart Fail., 10, p. 1314, DOI: 10.1002/ehf2.14298 190 10.1002/ehf2.14298 false true Reference 70713211 /api/reference/70713211 191. Kocabas 2025: Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study., ESC Heart Fail., 12, p. 434, DOI: 10.1002/ehf2.15049 191 10.1002/ehf2.15049 false true Reference 70713212 /api/reference/70713212 192. Kolovos 2023: Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%., ESC Heart Fail., 10, p. 3385, DOI: 10.1002/ehf2.14470 192 10.1002/ehf2.14470 false true Reference 70713213 /api/reference/70713213 193. Li 2024: SGLT2 inhibition, blood lipids, and cardiovascular disease: A Mendelian randomization study., ESC Heart Fail., 11, p. 3960, DOI: 10.1002/ehf2.14987 193 10.1002/ehf2.14987 false true Reference 70713214 /api/reference/70713214 194. Moroney 2023: Impact of diabetes duration on left ventricular mass regression with empagliflozin., ESC Heart Fail., 10, p. 2134, DOI: 10.1002/ehf2.14357 194 10.1002/ehf2.14357 false true Reference 70713215 /api/reference/70713215 195. Puar 2023: IGFBP7 and left ventricular mass regression: A sub-analysis of the EMPA-HEART CardioLink-6 randomized clinical trial., ESC Heart Fail., 10, p. 2113, DOI: 10.1002/ehf2.14335 195 10.1002/ehf2.14335 false true Reference 70713216 /api/reference/70713216 196. Savage 2024: Impact of SGLT2 inhibition on markers of reverse cardiac remodelling in heart failure: Systematic review and meta-analysis., ESC Heart Fail., 11, p. 3636, DOI: 10.1002/ehf2.14993 196 10.1002/ehf2.14993 false true Reference 70713217 /api/reference/70713217 197. Tang 2023: Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction., ESC Heart Fail., 10, p. 2524, DOI: 10.1002/ehf2.14426 197 10.1002/ehf2.14426 false true Reference 70713218 /api/reference/70713218 198. Tsutsui 2024: Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction., ESC Heart Fail., 11, p. 261, DOI: 10.1002/ehf2.14565 198 10.1002/ehf2.14565 false true Reference 70713219 /api/reference/70713219 199. Verma 2023: Baseline neutrophil-to-lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling., ESC Heart Fail., 10, p. 2127, DOI: 10.1002/ehf2.14351 199 10.1002/ehf2.14351 false true Reference 70713220 /api/reference/70713220 200. Avula 2024: SGLT2 Inhibitor Use and Risk of Clinical Events in Patients with Cancer Therapy–Related Cardiac Dysfunction., JACC Heart Fail., 12, p. 67, DOI: 10.1016/j.jchf.2023.08.026 200 10.1016/j.jchf.2023.08.026 false true Reference 70713221 /api/reference/70713221 201. Banner 2023: Will the SGLT2i Responders Please Stand Up?., Circ. Heart Fail., 16, p. e011124, DOI: 10.1161/CIRCHEARTFAILURE.123.011124 201 10.1161/CIRCHEARTFAILURE.123.011124 false true Reference 70713222 /api/reference/70713222 202. Biegus 2024: Decongestion in acute heart failure: Is it time to change diuretic-centred paradigm?., Eur. J. Heart Fail., 26, p. 2094, DOI: 10.1002/ejhf.3423 202 10.1002/ejhf.3423 false true Reference 70713223 /api/reference/70713223 203. Biegus 2023: Sodium–glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies., Eur. J. Heart Fail., 25, p. 1526, DOI: 10.1002/ejhf.2967 203 10.1002/ejhf.2967 false true Reference 70713224 /api/reference/70713224 204. Biegus 2023: Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial., Eur. Heart J., 44, p. 41, DOI: 10.1093/eurheartj/ehac530 204 10.1093/eurheartj/ehac530 false true Reference 70713225 /api/reference/70713225 205. Butler 2023: Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial., Eur. J. Heart Fail., 25, p. 1375, DOI: 10.1002/ejhf.2922 205 10.1002/ejhf.2922 false true Reference 70713226 /api/reference/70713226 206. Carberry 2025: Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI)., Eur. J. Heart Fail., 27, p. 566, DOI: 10.1002/ejhf.3560 206 10.1002/ejhf.3560 false true Reference 70713227 /api/reference/70713227 207. Carson 2025: Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial., JACC Heart Fail., 13, p. 710, DOI: 10.1016/j.jchf.2024.10.021 207 10.1016/j.jchf.2024.10.021 false true Reference 70713228 /api/reference/70713228 208. Chatur 2023: Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial., Eur. J. Heart Fail., 25, p. 1170, DOI: 10.1002/ejhf.2915 208 10.1002/ejhf.2915 false true Reference 70713229 /api/reference/70713229 209. Ferreira 2023: Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: Findings from EMPULSE., Eur. J. Heart Fail., 25, p. 1797, DOI: 10.1002/ejhf.2982 209 10.1002/ejhf.2982 false true Reference 70713230 /api/reference/70713230 210. Ferreira 2024: Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE., Eur. J. Heart Fail., 26, p. 1976 210 false true Reference 70713231 /api/reference/70713231 211. Ferreira 2024: Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program., Eur. J. Heart Fail., 26, p. 155, DOI: 10.1002/ejhf.3078 211 10.1002/ejhf.3078 false true Reference 70713232 /api/reference/70713232 212. Filippatos 2023: Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation., Eur. J. Heart Fail., 25, p. 970, DOI: 10.1002/ejhf.2861 212 10.1002/ejhf.2861 false true Reference 70713233 /api/reference/70713233 213. Hussain 2023: Utilization Rates of SGLT2 Inhibitors Among Patients with Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease., JACC Heart Fail., 11, p. 933, DOI: 10.1016/j.jchf.2023.03.024 213 10.1016/j.jchf.2023.03.024 false true Reference 70713234 /api/reference/70713234 214. Kittipibul 2024: Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset with SGLT2i Therapy., JACC Heart Fail., 12, p. 1409, DOI: 10.1016/j.jchf.2024.04.003 214 10.1016/j.jchf.2024.04.003 false true Reference 70713235 /api/reference/70713235 215. Kosiborod 2022: Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial., Circulation, 146, p. 279, DOI: 10.1161/CIRCULATIONAHA.122.059725 215 10.1161/CIRCULATIONAHA.122.059725 false true Reference 70713236 /api/reference/70713236 216. Lewis 2023: Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure with Preserved Ejection Fraction: PRESERVED-HF., Circ Heart Fail., 16, p. e010633, DOI: 10.1161/CIRCHEARTFAILURE.123.010633 216 10.1161/CIRCHEARTFAILURE.123.010633 false true Reference 70713237 /api/reference/70713237 217. Mastrangelo 2025: SGLT2i Therapy Prevents Anthracycline-Induced Cardiotoxicity in a Large Animal Model by Preserving Myocardial Energetics., JACC CardioOncology, 7, p. 171, DOI: 10.1016/j.jaccao.2024.12.004 217 10.1016/j.jaccao.2024.12.004 false true Reference 70713238 /api/reference/70713238 218. Nassif 2023: Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials., Circ. Heart Fail., 16, p. e009837, DOI: 10.1161/CIRCHEARTFAILURE.122.009837 218 10.1161/CIRCHEARTFAILURE.122.009837 false true Reference 70713239 /api/reference/70713239 219. Peikert 2024: Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER., Eur. J. Heart Fail., 26, p. 912, DOI: 10.1002/ejhf.3184 219 10.1002/ejhf.3184 false true Reference 70713240 /api/reference/70713240 220. Pierce 2023: Implementation of sodium–glucose cotransporter 2 inhibitors for heart failure with reduced ejection fraction: Where we are versus where we need to be., Eur. J. Heart Fail., 25, p. 1659, DOI: 10.1002/ejhf.2999 220 10.1002/ejhf.2999 false true Reference 70713241 /api/reference/70713241 221. Pitt 2023: Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events., JACC Heart Fail., 11, p. 879, DOI: 10.1016/j.jchf.2023.05.026 221 10.1016/j.jchf.2023.05.026 false true Reference 70713242 /api/reference/70713242 222. Porcari 2024: SGLT2 Inhibitor Therapy in Patients with Transthyretin Amyloid Cardiomyopathy., J. Am. Coll. Cardiol., 83, p. 2411, DOI: 10.1016/j.jacc.2024.03.429 222 10.1016/j.jacc.2024.03.429 false true Reference 70713243 /api/reference/70713243 223. Sattar 2024: Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial., Eur. J. Heart Fail., 26, p. 900, DOI: 10.1002/ejhf.3221 223 10.1002/ejhf.3221 false true Reference 70713244 /api/reference/70713244 224. Schauer 2024: Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain., Circ. Heart Fail., 17, p. e011107, DOI: 10.1161/CIRCHEARTFAILURE.123.011107 224 10.1161/CIRCHEARTFAILURE.123.011107 false true Reference 70713245 /api/reference/70713245 225. Selvaraj 2024: Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction., Circ. Heart Fail., 17, p. e011980, DOI: 10.1161/CIRCHEARTFAILURE.124.011980 225 10.1161/CIRCHEARTFAILURE.124.011980 false true Reference 70713246 /api/reference/70713246 226. Sharma 2023: Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from the EMPEROR-Preserved trial., Eur. J. Heart Fail., 25, p. 1337, DOI: 10.1002/ejhf.2857 226 10.1002/ejhf.2857 false true Reference 70713247 /api/reference/70713247 227. Tromp 2024: Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction—Results from the EMPULSE trial., Eur. J. Heart Fail., 26, p. 963, DOI: 10.1002/ejhf.3218 227 10.1002/ejhf.3218 false true Reference 70713248 /api/reference/70713248 228. Usman 2024: The effect of sodium–glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta-analysis., Eur. J. Heart Fail., 26, p. 373, DOI: 10.1002/ejhf.3129 228 10.1002/ejhf.3129 false true Reference 70713249 /api/reference/70713249 229. Vaduganathan 2024: Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial., Eur. J. Heart Fail., 26, p. 1967 229 false true Reference 70713250 /api/reference/70713250 230. Weintraub 2024: Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF., JACC Heart Fail., 12, p. 1600, DOI: 10.1016/j.jchf.2024.04.018 230 10.1016/j.jchf.2024.04.018 false true Reference 70713251 /api/reference/70713251 231. Wiggers 2024: SGLT2 Inhibitors and Their Effect on Metabolism in Patients with Heart Failure., Circ. Heart Fail., 17, p. e012373, DOI: 10.1161/CIRCHEARTFAILURE.124.012373 231 10.1161/CIRCHEARTFAILURE.124.012373 false true Reference 70713252 /api/reference/70713252 232. Wood 2024: Sodium–glucose cotransporter 2 inhibitors influence skeletal muscle pathology in patients with heart failure and reduced ejection fraction., Eur. J. Heart Fail., 26, p. 925, DOI: 10.1002/ejhf.3192 232 10.1002/ejhf.3192 false true Reference 70713253 /api/reference/70713253 233. Novo 2025: Effects of sodium–glucose cotransporter 2 inhibitors in patients with cancer and diabetes mellitus: A systematic review and meta-analysis., Eur. Heart J.-Cardiovasc. Pharmacother., 11, p. 343, DOI: 10.1093/ehjcvp/pvaf028 233 10.1093/ehjcvp/pvaf028 false true Reference 70713254 /api/reference/70713254 234. Nuzzi 2024: SGLT2 inhibitor therapy in patients with advanced heart failure and reduced ejection fraction., Curr. Probl. Cardiol., 49, p. 102823, DOI: 10.1016/j.cpcardiol.2024.102823 234 10.1016/j.cpcardiol.2024.102823 false true Reference 70713255 /api/reference/70713255 235. Butt 2024: Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan., ESC Heart Fail., 11, p. 65, DOI: 10.1002/ehf2.14558 235 10.1002/ehf2.14558 false true Reference 70713256 /api/reference/70713256 236. Improta 2025: The in-hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta-analysis., ESC Heart Fail., 12, p. 998, DOI: 10.1002/ehf2.15082 236 10.1002/ehf2.15082 false true Reference 70713257 /api/reference/70713257 237. Fabiani 2023: Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan., ESC Heart Fail., 10, p. 2927, DOI: 10.1002/ehf2.14346 237 10.1002/ehf2.14346 false true Reference 70713258 /api/reference/70713258 238. Iacoviello 2024: Pharmacoutilization and adherence to sacubitril/valsartan in real world: The REAL.IT study in HFrEF., ESC Heart Fail., 11, p. 456, DOI: 10.1002/ehf2.14600 238 10.1002/ehf2.14600 false true Reference 70713259 /api/reference/70713259 239. Liu 2024: Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF., ESC Heart Fail., 11, p. 937, DOI: 10.1002/ehf2.14646 239 10.1002/ehf2.14646 false true Reference 70713260 /api/reference/70713260 240. Mapelli 2023: Dramatic disease regression in a case of HFrEF with end-stage renal failure treated with sacubitril/valsartan and SGLT2i., ESC Heart Fail., 10, p. 2099, DOI: 10.1002/ehf2.14344 240 10.1002/ehf2.14344 false true Reference 70713261 /api/reference/70713261 241. Mohebi 2023: Importance of the ‘area under the curve’ from serial NT-proBNP measurements during treatment with sacubitril/valsartan., ESC Heart Fail., 10, p. 3133, DOI: 10.1002/ehf2.14503 241 10.1002/ehf2.14503 false true Reference 70713262 /api/reference/70713262 242. Bendiksen 2025: Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats., ESC Heart Fail., 12, p. 1304, DOI: 10.1002/ehf2.15145 242 10.1002/ehf2.15145 false true Reference 70713263 /api/reference/70713263 243. Tajstra 2023: Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): Design and rationale of the randomized trial., ESC Heart Fail., 10, p. 3174, DOI: 10.1002/ehf2.14466 243 10.1002/ehf2.14466 false true Reference 70713264 /api/reference/70713264 244. Wang 2023: Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: A real-world study., ESC Heart Fail., 10, p. 1961, DOI: 10.1002/ehf2.14367 244 10.1002/ehf2.14367 false true Reference 70713265 /api/reference/70713265 245. Rosano 2022: “Impact analysis of heart failure across European countries: An ESC-HFA position paper” and “Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan”., ESC Heart Fail., 9, p. 2767, DOI: 10.1002/ehf2.14076 245 10.1002/ehf2.14076 false true Reference 70713266 /api/reference/70713266 246. Biegus 2025: Diuretic De-Escalation in Response to HF Therapy., JACC Heart Fail., 13, p. 846, DOI: 10.1016/j.jchf.2025.03.010 246 10.1016/j.jchf.2025.03.010 false true Reference 70713267 /api/reference/70713267 247. Biegus 2024: Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF., J. Am. Coll. Cardiol., 84, p. 323, DOI: 10.1016/j.jacc.2024.04.055 247 10.1016/j.jacc.2024.04.055 false true Reference 70713268 /api/reference/70713268 248. Bozkurt 2023: Neprilysin Inhibitors in Heart Failure., JACC Basic Transl. Sci., 8, p. 88, DOI: 10.1016/j.jacbts.2022.05.010 248 10.1016/j.jacbts.2022.05.010 false true Reference 70713269 /api/reference/70713269 249. Kondo 2025: Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF., JACC Heart Fail., 13, p. 927, DOI: 10.1016/j.jchf.2024.12.010 249 10.1016/j.jchf.2024.12.010 false true Reference 70713270 /api/reference/70713270 250. Mebazaa 2024: Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATRIUM-HF study., Eur. J. Heart Fail., 26, p. 1507, DOI: 10.1002/ejhf.3265 250 10.1002/ejhf.3265 false true Reference 70713271 /api/reference/70713271 251. Mentz 2023: Angiotensin-Neprilysin Inhibition in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure., J. Am. Coll. Cardiol., 82, p. 1, DOI: 10.1016/j.jacc.2023.04.019 251 10.1016/j.jacc.2023.04.019 false true Reference 70713272 /api/reference/70713272 252. Rajzer 2025: Sacubitril/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations)., Heart Fail. Rev., 30, p. 387, DOI: 10.1007/s10741-024-10471-1 252 10.1007/s10741-024-10471-1 false true Reference 70713273 /api/reference/70713273 253. Shaddy 2024: Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial., Circulation, 150, p. 1756, DOI: 10.1161/CIRCULATIONAHA.123.066605 253 10.1161/CIRCULATIONAHA.123.066605 false true Reference 70713274 /api/reference/70713274 254. Stolfo 2024: Status and timing of angiotensin receptor–neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry., Eur. J. Heart Fail., 26, p. 2243, DOI: 10.1002/ejhf.3404 254 10.1002/ejhf.3404 false true Reference 70713275 /api/reference/70713275 255. Velicki 2024: Sacubitril/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: An open label randomized controlled trial (SILICOFCM)., Eur. J. Heart Fail., 26, p. 1361, DOI: 10.1002/ejhf.3291 255 10.1002/ejhf.3291 false true Reference 70713276 /api/reference/70713276 256. Ventura 2023: Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction., J. Am. Coll. Cardiol., 82, p. 13, DOI: 10.1016/j.jacc.2023.05.002 256 10.1016/j.jacc.2023.05.002 false true Reference 70713277 /api/reference/70713277 257. Ahmed 2025: Intravenous iron therapy for heart failure and iron deficiency: An updated meta-analysis of randomized clinical trials., ESC Heart Fail., 12, p. 43, DOI: 10.1002/ehf2.14905 257 10.1002/ehf2.14905 false true Reference 70713278 /api/reference/70713278 258. Bakogiannis 2023: Iron therapy and severe arrhythmias in HFrEF: Rationale, study design, and baseline results of the RESAFE-HF trial., ESC Heart Fail., 10, p. 1184, DOI: 10.1002/ehf2.14276 258 10.1002/ehf2.14276 false true Reference 70713279 /api/reference/70713279 259. Cabrera 2024: Iron deficiency in new onset heart failure: Association with clinical factors and quality of life., ESC Heart Fail., 11, p. 2661, DOI: 10.1002/ehf2.14849 259 10.1002/ehf2.14849 false true Reference 70713280 /api/reference/70713280 260. Docherty 2024: Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction., ESC Heart Fail., 11, p. 1875, DOI: 10.1002/ehf2.14742 260 10.1002/ehf2.14742 false true Reference 70713281 /api/reference/70713281 261. Gertler 2023: Magnetic resonance imaging of organ iron before and after correction of iron deficiency in patients with heart failure., ESC Heart Fail., 10, p. 1847, DOI: 10.1002/ehf2.14329 261 10.1002/ehf2.14329 false true Reference 70713282 /api/reference/70713282 262. Graham 2023: Influence of serum transferrin concentration on diagnostic criteria for iron deficiency in chronic heart failure., ESC Heart Fail., 10, p. 2826, DOI: 10.1002/ehf2.14438 262 10.1002/ehf2.14438 false true Reference 70713283 /api/reference/70713283 263. Mohamed 2025: Prognostic impact of iron deficiency in new-onset chronic heart failure: Danish Heart Failure Registry insights., ESC Heart Fail., 12, p. 1346, DOI: 10.1002/ehf2.15149 263 10.1002/ehf2.15149 false true Reference 70713284 /api/reference/70713284 264. Ohori 2024: Relationship between serum iron level and physical function in heart failure patients is lost by presence of diabetes., ESC Heart Fail., 11, p. 513, DOI: 10.1002/ehf2.14610 264 10.1002/ehf2.14610 false true Reference 70713285 /api/reference/70713285 265. Rosano 2023: Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials., ESC Heart Fail., 10, p. 1294, DOI: 10.1002/ehf2.14286 265 10.1002/ehf2.14286 false true Reference 70713286 /api/reference/70713286 266. Salah 2023: Intravenous iron infusion in patients with heart failure: A systematic review and study-level meta-analysis., ESC Heart Fail., 10, p. 1473, DOI: 10.1002/ehf2.14310 266 10.1002/ehf2.14310 false true Reference 70713287 /api/reference/70713287 267. Santas 2024: Improvement in left atrial strain following ferric carboxymaltose in heart failure: An analysis of the Myocardial-IRON trial., ESC Heart Fail., 11, p. 1258, DOI: 10.1002/ehf2.14630 267 10.1002/ehf2.14630 false true Reference 70713288 /api/reference/70713288 268. Sharma 2024: Iron Deficiency and Incident Heart Failure in Older Community-Dwelling Individuals., ESC Heart Fail., 11, p. 1435, DOI: 10.1002/ehf2.14724 268 10.1002/ehf2.14724 false true Reference 70713289 /api/reference/70713289 269. 2025: Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities., ESC Heart Fail., 12, p. 723, DOI: 10.1002/ehf2.15157 269 10.1002/ehf2.15157 false true Reference 70713290 /api/reference/70713290 270. Anker 2023: Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta-analysis., Eur. J. Heart Fail., 25, p. 1080, DOI: 10.1002/ejhf.2860 270 10.1002/ejhf.2860 false true Reference 70713291 /api/reference/70713291 271. Biegus 2023: Striving for the ‘perfect’ definition of iron deficiency in heart failure., Eur. J. Heart Fail., 25, p. 2075, DOI: 10.1002/ejhf.3051 271 10.1002/ejhf.3051 false true Reference 70713292 /api/reference/70713292 272. Camilli 2025: Iron deficiency and supplementation in patients with heart failure: Results from the IRON-HF international survey., Eur. J. Heart Fail., 27, p. 140, DOI: 10.1002/ejhf.3356 272 10.1002/ejhf.3356 false true Reference 70713293 /api/reference/70713293 273. Cheema 2024: Intravenous Iron Repletion for Patients with Heart Failure and Iron Deficiency., J. Am. Coll. Cardiol., 83, p. 2674, DOI: 10.1016/j.jacc.2024.03.431 273 10.1016/j.jacc.2024.03.431 false true Reference 70713294 /api/reference/70713294 274. Pellicori 2025: Associations of iron deficiency with cardiac function, congestion, exercise capacity and prognosis in heart failure., Eur. J. Heart Fail., 27, p. 889, DOI: 10.1002/ejhf.3534 274 10.1002/ejhf.3534 false true Reference 70713295 /api/reference/70713295 275. Foley 2025: Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trial., Eur. J. Heart Fail., 27, p. 166, DOI: 10.1002/ejhf.3504 275 10.1002/ejhf.3504 false true Reference 70713296 /api/reference/70713296 276. Graham 2023: Intravenous iron in patients with heart failure and iron deficiency: An updated meta-analysis., Eur. J. Heart Fail., 25, p. 528, DOI: 10.1002/ejhf.2810 276 10.1002/ejhf.2810 false true Reference 70713297 /api/reference/70713297 277. Kalogeropoulos 2023: Benefits of intravenous iron supplementation in patients with heart failure: Mounting evidence and open questions., Eur. J. Heart Fail., 25, p. 538, DOI: 10.1002/ejhf.2787 277 10.1002/ejhf.2787 false true Reference 70713298 /api/reference/70713298 278. Kido 2024: Management of Iron Deficiency in Heart Failure., JACC Heart Fail., 12, p. 1961, DOI: 10.1016/j.jchf.2024.05.014 278 10.1016/j.jchf.2024.05.014 false true Reference 70713299 /api/reference/70713299 279. Lindberg 2023: Iron deficiency in heart failure: Screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborative project., Eur. J. Heart Fail., 25, p. 1270, DOI: 10.1002/ejhf.2879 279 10.1002/ejhf.2879 false true Reference 70713300 /api/reference/70713300 280. Marques 2023: Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium–glucose cotransporter 2 inhibitors., Eur. J. Heart Fail., 25, p. 2191, DOI: 10.1002/ejhf.2992 280 10.1002/ejhf.2992 false true Reference 70713301 /api/reference/70713301 281. Martens 2024: Defining Iron Deficiency in Heart Failure: Importance of Transferrin Saturation., Circ. Heart Fail., 17, p. e011440, DOI: 10.1161/CIRCHEARTFAILURE.123.011440 281 10.1161/CIRCHEARTFAILURE.123.011440 false true Reference 70713302 /api/reference/70713302 282. Masini 2022: Criteria for Iron Deficiency in Patients with Heart Failure., J. Am. Coll. Cardiol., 79, p. 341, DOI: 10.1016/j.jacc.2021.11.039 282 10.1016/j.jacc.2021.11.039 false true Reference 70713303 /api/reference/70713303 283. Nouhravesh 2025: Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID., Eur. J. Heart Fail., 27, p. 872, DOI: 10.1002/ejhf.3348 283 10.1002/ejhf.3348 false true Reference 70713304 /api/reference/70713304 284. Packer 2023: Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure., JACC Heart Fail., 11, p. 106, DOI: 10.1016/j.jchf.2022.10.004 284 10.1016/j.jchf.2022.10.004 false true Reference 70713305 /api/reference/70713305 285. Packer 2024: Iron homeostasis, recycling and vulnerability in the stressed kidney: A neglected dimension of iron-deficient heart failure., Eur. J. Heart Fail., 26, p. 1631, DOI: 10.1002/ejhf.3238 285 10.1002/ejhf.3238 false true Reference 70713306 /api/reference/70713306 286. Packer 2024: Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure., Eur. J. Heart Fail., 26, p. 1298, DOI: 10.1002/ejhf.3237 286 10.1002/ejhf.3237 false true Reference 70713307 /api/reference/70713307 287. Packer 2024: Redefining Iron Deficiency in Patients with Chronic Heart Failure., Circulation, 150, p. 151, DOI: 10.1161/CIRCULATIONAHA.124.068883 287 10.1161/CIRCULATIONAHA.124.068883 false true Reference 70713308 /api/reference/70713308 288. Papadopoulou 2023: Prognostic value of three iron deficiency definitions in patients with advanced heart failure., Eur. J. Heart Fail., 25, p. 2067, DOI: 10.1002/ejhf.2949 288 10.1002/ejhf.2949 false true Reference 70713309 /api/reference/70713309 289. Savarese 2023: Sodium–glucose cotransporter 2 inhibitors on top of intravenous iron in patients with heart failure and iron deficiency: Any incremental effect?., Eur. J. Heart Fail., 25, p. 2199, DOI: 10.1002/ejhf.3064 289 10.1002/ejhf.3064 false true Reference 70713310 /api/reference/70713310 290. Aaseth 2024: Prevalence of transthyretin amyloid cardiomyopathy in pacemaker patients., ESC Heart Fail., 11, p. 871, DOI: 10.1002/ehf2.14645 290 10.1002/ehf2.14645 false true Reference 70713311 /api/reference/70713311 291. Ahmad 2024: First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia., ESC Heart Fail., 11, p. 4348, DOI: 10.1002/ehf2.15045 291 10.1002/ehf2.15045 false true Reference 70713312 /api/reference/70713312 292. Alonso 2024: Transthyretin cardiac amyloid: Broad heart failure phenotypic spectrum and implications for diagnosis., ESC Heart Fail., 11, p. 3649, DOI: 10.1002/ehf2.15035 292 10.1002/ehf2.15035 false true Reference 70713313 /api/reference/70713313 293. Amadio 2025: Predictors of mortality by an artificial intelligence enhanced electrocardiogram model for cardiac amyloidosis., ESC Heart Fail., 12, p. 677, DOI: 10.1002/ehf2.15061 293 10.1002/ehf2.15061 false true Reference 70713314 /api/reference/70713314 294. Antonopoulos 2025: A phenomap of TTR amyloidosis to aid diagnostic screening., ESC Heart Fail., 12, p. 1113, DOI: 10.1002/ehf2.15143 294 10.1002/ehf2.15143 false true Reference 70713315 /api/reference/70713315 295. Zampieri 2025: Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis., ESC Heart Fail., 12, p. 809, DOI: 10.1002/ehf2.14684 295 10.1002/ehf2.14684 false true Reference 70713316 /api/reference/70713316 296. Berthelot 2023: Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure., ESC Heart Fail., 10, p. 2042, DOI: 10.1002/ehf2.14337 296 10.1002/ehf2.14337 false true Reference 70713317 /api/reference/70713317 297. Beuthner 2024: Histological assessment of cardiac amyloidosis in patients undergoing transcatheter aortic valve replacement., ESC Heart Fail., 11, p. 1636, DOI: 10.1002/ehf2.14709 297 10.1002/ehf2.14709 false true Reference 70713318 /api/reference/70713318 298. Broussier 2025: Frailty in heart failure according to the presence or absence of wild-type transthyretin cardiac amyloidosis., ESC Heart Fail., 12, p. 281, DOI: 10.1002/ehf2.15026 298 10.1002/ehf2.15026 false true Reference 70713319 /api/reference/70713319 299. Cantone 2023: Cardiopulmonary exercise testing predicts prognosis in amyloid cardiomyopathy: A systematic review and meta-analysis., ESC Heart Fail., 10, p. 2740, DOI: 10.1002/ehf2.14406 299 10.1002/ehf2.14406 false true Reference 70713320 /api/reference/70713320 300. Casian 2024: Too young for an acquired cardiomyopathy? Cobalt metallosis as a cardiac amyloidosis mimicker., ESC Heart Fail., 11, p. 1236, DOI: 10.1002/ehf2.14695 300 10.1002/ehf2.14695 false true Reference 70713321 /api/reference/70713321 301. Dobner 2024: Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy., ESC Heart Fail., 11, p. 2759, DOI: 10.1002/ehf2.14815 301 10.1002/ehf2.14815 false true Reference 70713322 /api/reference/70713322 302. Eldhagen 2023: Health-related quality of life among transthyretin amyloid cardiomyopathy patients., ESC Heart Fail., 10, p. 1871, DOI: 10.1002/ehf2.14350 302 10.1002/ehf2.14350 false true Reference 70713323 /api/reference/70713323 303. Ferkh 2024: Diagnostic and prognostic value of the left atrial myopathy evaluation in cardiac amyloidosis using echocardiography., ESC Heart Fail., 11, p. 4139, DOI: 10.1002/ehf2.15013 303 10.1002/ehf2.15013 false true Reference 70713324 /api/reference/70713324 304. Formiga 2024: Musculoskeletal co-morbidities in patients with transthyretin amyloid cardiomyopathy: A systematic review., ESC Heart Fail., 11, p. 662, DOI: 10.1002/ehf2.14622 304 10.1002/ehf2.14622 false true Reference 70713325 /api/reference/70713325 305. Gioia 2024: Transthyretin amyloid cardiomyopathy among patients with heart failure and preserved ejection fraction: The AMY score., ESC Heart Fail., 11, p. 2172, DOI: 10.1002/ehf2.14786 305 10.1002/ehf2.14786 false true Reference 70713326 /api/reference/70713326 306. Healy 2025: Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction., ESC Heart Fail., 12, p. 1176, DOI: 10.1002/ehf2.15112 306 10.1002/ehf2.15112 false true Reference 70713327 /api/reference/70713327 307. Holcman 2025: Advancing diagnostics and therapy in transthyretin amyloid cardiomyopathy., ESC Heart Fail., 12, p. 1529, DOI: 10.1002/ehf2.15166 307 10.1002/ehf2.15166 false true Reference 70713328 /api/reference/70713328 308. Holt 2024: Invasive haemodynamics at rest and exercise in cardiac amyloidosis., ESC Heart Fail., 11, p. 1263, DOI: 10.1002/ehf2.14621 308 10.1002/ehf2.14621 false true Reference 70713329 /api/reference/70713329 309. Izumiya 2025: Transthyretin amyloid cardiomyopathy: Literature review and red-flag symptom clusters for each cardiology specialty., ESC Heart Fail., 12, p. 955, DOI: 10.1002/ehf2.15016 309 10.1002/ehf2.15016 false true Reference 70713330 /api/reference/70713330 310. Kato 2024: Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan., ESC Heart Fail., 11, p. 2881, DOI: 10.1002/ehf2.14736 310 10.1002/ehf2.14736 false true Reference 70713331 /api/reference/70713331 311. Kwok 2024: Effect of beta-blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta-analysis., ESC Heart Fail., 11, p. 3901, DOI: 10.1002/ehf2.14975 311 10.1002/ehf2.14975 false true Reference 70713332 /api/reference/70713332 312. Ladefoged 2025: The effect of trimetazidine on cardiac haemodynamics and mitochondrial function in wild-type transthyretin amyloidosis., ESC Heart Fail., 12, p. 1796, DOI: 10.1002/ehf2.15181 312 10.1002/ehf2.15181 false true Reference 70713333 /api/reference/70713333 313. Leo 2023: Estimating nuclear scanning capacity requirements for patients with suspected cardiac transthyretin amyloidosis., ESC Heart Fail., 10, p. 1492, DOI: 10.1002/ehf2.14315 313 10.1002/ehf2.14315 false true Reference 70713334 /api/reference/70713334 314. Li 2024: Dapagliflozin treatment and cardiovascular outcome in RBP4/TTRVal30Met (transthyretin cardiac amyloidosis) mice., ESC Heart Fail., 11, p. 179, DOI: 10.1002/ehf2.14567 314 10.1002/ehf2.14567 false true Reference 70713335 /api/reference/70713335 315. Moya 2023: Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records., ESC Heart Fail., 10, p. 3483, DOI: 10.1002/ehf2.14517 315 10.1002/ehf2.14517 false true Reference 70713336 /api/reference/70713336 316. Naito 2023: Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan., ESC Heart Fail., 10, p. 1896, DOI: 10.1002/ehf2.14364 316 10.1002/ehf2.14364 false true Reference 70713337 /api/reference/70713337 317. Neculae 2024: Cardiac amyloidosis is not a single disease: A multiparametric comparison between the light chain and transthyretin forms., ESC Heart Fail., 11, p. 2825, DOI: 10.1002/ehf2.14852 317 10.1002/ehf2.14852 false true Reference 70713338 /api/reference/70713338 318. Nies 2025: Real-world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study., ESC Heart Fail., 12, p. 1203, DOI: 10.1002/ehf2.15126 318 10.1002/ehf2.15126 false true Reference 70713339 /api/reference/70713339 319. Ochi 2024: Importance of fourth heart sound and preserved left atrial function in wild-type transthyretin amyloidosis., ESC Heart Fail., 11, p. 4000, DOI: 10.1002/ehf2.14937 319 10.1002/ehf2.14937 false true Reference 70713340 /api/reference/70713340 320. Rosengren 2024: Outcome prediction by myocardial external efficiency from 11C-acetate positron emission tomography in cardiac amyloidosis., ESC Heart Fail., 11, p. 44, DOI: 10.1002/ehf2.14545 320 10.1002/ehf2.14545 false true Reference 70713341 /api/reference/70713341 321. Sha 2024: Biochemical and biophysical properties of a rare TTRA81V mutation causing mild transthyretin amyloid cardiomyopathy., ESC Heart Fail., 11, p. 112, DOI: 10.1002/ehf2.14543 321 10.1002/ehf2.14543 false true Reference 70713342 /api/reference/70713342 322. Takashio 2023: Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy., ESC Heart Fail., 10, p. 2319, DOI: 10.1002/ehf2.14380 322 10.1002/ehf2.14380 false true Reference 70713343 /api/reference/70713343 323. Tini 2025: Early diagnosis, disease stage and prognosis in wild-type transthyretin amyloid cardiomyopathy: The DIAMOND study., ESC Heart Fail., 12, p. 379, DOI: 10.1002/ehf2.15091 323 10.1002/ehf2.15091 false true Reference 70713344 /api/reference/70713344 324. Usuku 2024: A new staging system using right atrial strain in patients with immunoglobulin light-chain cardiac amyloidosis., ESC Heart Fail., 11, p. 1612, DOI: 10.1002/ehf2.14710 324 10.1002/ehf2.14710 false true Reference 70713345 /api/reference/70713345 325. Vereckei 2024: Novel electrocardiographic criteria may render possible the more accurate recognition of cardiac amyloidosis., ESC Heart Fail., 11, p. 1030, DOI: 10.1002/ehf2.14655 325 10.1002/ehf2.14655 false true Reference 70713346 /api/reference/70713346 326. Willixhofer 2025: Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study., ESC Heart Fail., 12, p. 1326, DOI: 10.1002/ehf2.15147 326 10.1002/ehf2.15147 false true Reference 70713347 /api/reference/70713347 327. Zaroui 2024: Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study., ESC Heart Fail., 11, p. 1707, DOI: 10.1002/ehf2.14671 327 10.1002/ehf2.14671 false true Reference 70713348 /api/reference/70713348 328. Aimo 2024: Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients with Cardiac Amyloidosis., JACC CardioOncology, 6, p. 797, DOI: 10.1016/j.jaccao.2024.07.009 328 10.1016/j.jaccao.2024.07.009 false true Reference 70713349 /api/reference/70713349 329. Aimo 2025: Cardiac Biomarkers in Patients with Suspected Amyloid (Transthyretin) Cardiomyopathy., JACC CardioOncology, 7, p. 451, DOI: 10.1016/j.jaccao.2025.02.007 329 10.1016/j.jaccao.2025.02.007 false true Reference 70713350 /api/reference/70713350 330. Bonfioli, G.B., Tomasoni, D., Vergaro, G., Castiglione, V., Adamo, M., Fabiani, I., Loghin, V., Lombardi, C.M., Nicolai, A., and Metra, M. (2024). The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis. Eur. J. Heart Fail., ejhf.3455., DOI: 10.1002/ejhf.3455 330 10.1002/ejhf.3455 false true Reference 70713351 /api/reference/70713351 331. Chacko 2024: Myocardial perfusion in cardiac amyloidosis., Eur. J. Heart Fail., 26, p. 598, DOI: 10.1002/ejhf.3137 331 10.1002/ejhf.3137 false true Reference 70713352 /api/reference/70713352 332. Cipriani 2024: Cardiac Troponin in Patients with Light Chain and Transthyretin Cardiac Amyloidosis., JACC CardioOncology, 6, p. 1, DOI: 10.1016/j.jaccao.2023.12.006 332 10.1016/j.jaccao.2023.12.006 false true Reference 70713353 /api/reference/70713353 333. Sinigiani 2025: High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy., Circ Heart Fail., 18, p. e012816 333 false true Reference 70713354 /api/reference/70713354 334. Drachman 2024: Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction., Eur. J. Heart Fail., 26, p. ejhf.3330, DOI: 10.1002/ejhf.3330 334 10.1002/ejhf.3330 false true Reference 70713355 /api/reference/70713355 335. Fine 2024: Atrial Fibrillation in Transthyretin Amyloid Cardiomyopathy., JACC CardioOncology, 6, p. 599, DOI: 10.1016/j.jaccao.2024.05.016 335 10.1016/j.jaccao.2024.05.016 false true Reference 70713356 /api/reference/70713356 336. Fontana 2025: Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis., Circ. Heart Fail., 18, p. e012112, DOI: 10.1161/CIRCHEARTFAILURE.124.012112 336 10.1161/CIRCHEARTFAILURE.124.012112 false true Reference 70713357 /api/reference/70713357 337. Fumagalli 2025: Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis., JACC CardioOncology, 7, p. 268, DOI: 10.1016/j.jaccao.2025.01.018 337 10.1016/j.jaccao.2025.01.018 false true Reference 70713358 /api/reference/70713358 338. McPhail 2024: Histological Typing in Patients with Cardiac Amyloidosis., J. Am. Coll. Cardiol., 83, p. 1085, DOI: 10.1016/j.jacc.2024.01.010 338 10.1016/j.jacc.2024.01.010 false true Reference 70713359 /api/reference/70713359 339. Gunn 2024: Light-Chain Pericardial Amyloidosis Emerging Alongside Variant Transthyretin Cardiac Amyloidosis., JACC CardioOncology, 6, p. 612, DOI: 10.1016/j.jaccao.2024.04.002 339 10.1016/j.jaccao.2024.04.002 false true Reference 70713360 /api/reference/70713360 340. Haring 2023: Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant., JACC Heart Fail., 11, p. 1189, DOI: 10.1016/j.jchf.2023.02.003 340 10.1016/j.jchf.2023.02.003 false true Reference 70713361 /api/reference/70713361 341. Ioannou 2024: Albuminuria in transthyretin cardiac amyloidosis: Prevalence, progression and prognostic importance., Eur. J. Heart Fail., 26, p. 65, DOI: 10.1002/ejhf.3094 341 10.1002/ejhf.3094 false true Reference 70713362 /api/reference/70713362 342. Kittleson 2023: 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient with Cardiac Amyloidosis., J. Am. Coll. Cardiol., 81, p. 1076, DOI: 10.1016/j.jacc.2022.11.022 342 10.1016/j.jacc.2022.11.022 false true Reference 70713363 /api/reference/70713363 343. Martyn 2024: Understanding Race, Genotype, and Socioeconomic Status in Transthyretin Amyloid Cardiomyopathy., JACC CardioOncology, 6, p. 464, DOI: 10.1016/j.jaccao.2024.05.006 343 10.1016/j.jaccao.2024.05.006 false true Reference 70713364 /api/reference/70713364 344. Masri 2025: A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy., JACC CardioOncology, 7, p. 282, DOI: 10.1016/j.jaccao.2024.12.005 344 10.1016/j.jaccao.2024.12.005 false true Reference 70713365 /api/reference/70713365 345. Netti, L., Ioannou, A., Martinez-Naharro, A., Razvi, Y., Porcari, A., Venneri, L., Maestrini, V., Knight, D., Virsinskaite, R., and Rauf, M.U. (2024). Microvascular obstruction in cardiac amyloidosis. Eur. J. Heart Fail., ejhf.3481., DOI: 10.1002/ejhf.3481 345 10.1002/ejhf.3481 false true Reference 70713366 /api/reference/70713366 346. Nitsche 2024: Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis., Eur. J. Heart Fail., 26, p. 2008 346 false true Reference 70713367 /api/reference/70713367 347. Razvi 2024: Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy., Circ. Heart Fail., 17, p. e012135, DOI: 10.1161/CIRCHEARTFAILURE.124.012135 347 10.1161/CIRCHEARTFAILURE.124.012135 false true Reference 70713368 /api/reference/70713368 348. Razvi 2025: Uncertain Clinical Relevance of Serial Bone Scintigraphy Findings in Treated Transthyretin Amyloid Cardiomyopathy., JACC Cardiovasc. Imaging, 18, p. 899, DOI: 10.1016/j.jcmg.2025.03.014 348 10.1016/j.jcmg.2025.03.014 false true Reference 70713369 /api/reference/70713369 349. Schilling 2024: The Pathophysiological and Therapeutic Implications of Cardiac Light-Chain Amyloidosis Compared with Transthyretin Amyloidosis., JACC Heart Fail., 12, p. 1781, DOI: 10.1016/j.jchf.2024.07.003 349 10.1016/j.jchf.2024.07.003 false true Reference 70713370 /api/reference/70713370 350. Shankar 2024: Race and Socioeconomic Status Impact Diagnosis and Clinical Outcomes in Transthyretin Cardiac Amyloidosis., JACC CardioOncology, 6, p. 454, DOI: 10.1016/j.jaccao.2024.05.001 350 10.1016/j.jaccao.2024.05.001 false true Reference 70713371 /api/reference/70713371 351. Tini 2023: Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: A multicentre network study., Eur. J. Heart Fail., 25, p. 845, DOI: 10.1002/ejhf.2823 351 10.1002/ejhf.2823 false true Reference 70713372 /api/reference/70713372 352. Vergaro 2023: N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis., Eur. J. Heart Fail., 25, p. 335, DOI: 10.1002/ejhf.2769 352 10.1002/ejhf.2769 false true Reference 70713373 /api/reference/70713373 353. Zweck 2024: Myocardial Mitochondrial Function Is Impaired in Cardiac Light-Chain Amyloidosis Compared to Transthyretin Amyloidosis., JACC Heart Fail., 12, p. 1778, DOI: 10.1016/j.jchf.2024.03.012 353 10.1016/j.jchf.2024.03.012 false true Reference 70713374 /api/reference/70713374 354. Witteles 2024: Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients with Transthyretin Amyloid Cardiomyopathy., JACC CardioOncology, 6, p. 592, DOI: 10.1016/j.jaccao.2024.03.007 354 10.1016/j.jaccao.2024.03.007 false true Reference 70713375 /api/reference/70713375 355. Bruns 2024: Insulin resistance in Takotsubo syndrome., ESC Heart Fail., 11, p. 1515, DOI: 10.1002/ehf2.14623 355 10.1002/ehf2.14623 false true Reference 70713376 /api/reference/70713376 356. Bruoha 2025: Takotsubo cardiomyopathy during armed conflict: A case series., ESC Heart Fail., 12, p. 1494, DOI: 10.1002/ehf2.15080 356 10.1002/ehf2.15080 false true Reference 70713377 /api/reference/70713377 357. Nickander 2023: Coronary microvascular dysfunction in Takotsubo syndrome and associations with left ventricular function., ESC Heart Fail., 10, p. 2395, DOI: 10.1002/ehf2.14394 357 10.1002/ehf2.14394 false true Reference 70713378 /api/reference/70713378 358. Li 2024: Takotsubo syndrome and vaccines: A systematic review., ESC Heart Fail., 11, p. 1795, DOI: 10.1002/ehf2.14719 358 10.1002/ehf2.14719 false true Reference 70713379 /api/reference/70713379 359. Lim 2024: Is index of microvascular resistance of Sisyphean utility in Takotsubo syndrome?., ESC Heart Fail., 11, p. 4438, DOI: 10.1002/ehf2.14943 359 10.1002/ehf2.14943 false true Reference 70713380 /api/reference/70713380 360. Petursson 2024: Effects of pharmacological interventions on mortality in patients with Takotsubo syndrome: A report from the SWEDEHEART registry., ESC Heart Fail., 11, p. 1720, DOI: 10.1002/ehf2.14713 360 10.1002/ehf2.14713 false true Reference 70713381 /api/reference/70713381 361. Pogran 2023: Takotsubo syndrome before and during the COVID-19 pandemic in Austria: A retrospective cohort study (TOSCA-19)., ESC Heart Fail., 10, p. 3667, DOI: 10.1002/ehf2.14536 361 10.1002/ehf2.14536 false true Reference 70713382 /api/reference/70713382 362. Solberg 2024: ESCHF-23-00103R1 ‘Microvascular function and inflammatory activation in Takotsubo cardiomyopathy’., ESC Heart Fail., 11, p. 1279, DOI: 10.1002/ehf2.14652 362 10.1002/ehf2.14652 false true Reference 70713383 /api/reference/70713383 363. Solberg 2023: Microvascular function and inflammatory activation in Takotsubo cardiomyopathy., ESC Heart Fail., 10, p. 3216, DOI: 10.1002/ehf2.14461 363 10.1002/ehf2.14461 false true Reference 70713384 /api/reference/70713384 364. Citro 2024: Cardiovascular Mortality in Takotsubo Syndrome., JACC Adv., 3, p. 100798, DOI: 10.1016/j.jacadv.2023.100798 364 10.1016/j.jacadv.2023.100798 false true Reference 70713385 /api/reference/70713385 365. Borovac 2023: A machine-learning-based prediction model in patients with takotsubo syndrome: ‘You can’t stop change any more than you can stop the suns from setting!’., Eur. J. Heart Fail., 25, p. 2312, DOI: 10.1002/ejhf.3069 365 10.1002/ejhf.3069 false true Reference 70713386 /api/reference/70713386 366. Cammann 2023: Machine learning-based prediction of in-hospital death for patients with takotsubo syndrome: The InterTAK-ML model., Eur. J. Heart Fail., 25, p. 2299, DOI: 10.1002/ejhf.2983 366 10.1002/ejhf.2983 false true Reference 70713387 /api/reference/70713387 367. Ferreira 2024: Mechanisms of myocardial reverse remodelling and its clinical significance: A scientific statement of the ESC Working Group on Myocardial Function., Eur. J. Heart Fail., 26, p. 1454, DOI: 10.1002/ejhf.3264 367 10.1002/ejhf.3264 false true Reference 70713388 /api/reference/70713388 368. Khan 2023: Structural and Functional Brain Changes in Acute Takotsubo Syndrome., JACC Heart Fail., 11, p. 307, DOI: 10.1016/j.jchf.2022.11.001 368 10.1016/j.jchf.2022.11.001 false true Reference 70713389 /api/reference/70713389 369. Polovina 2023: State-of-the-art document on optimal contemporary management of cardiomyopathies., Eur. J. Heart Fail., 25, p. 1899, DOI: 10.1002/ejhf.2979 369 10.1002/ejhf.2979 false true Reference 70713390 /api/reference/70713390 370. Singh 2022: Takotsubo Syndrome: Pathophysiology, Emerging Concepts, and Clinical Implications., Circulation, 145, p. 1002, DOI: 10.1161/CIRCULATIONAHA.121.055854 370 10.1161/CIRCULATIONAHA.121.055854 false true Reference 70713391 /api/reference/70713391 371. Abdu 2024: Association of liver fibrosis-4 index with adverse outcomes in hypertrophic cardiomyopathy patients., ESC Heart Fail., 11, p. 3934, DOI: 10.1002/ehf2.14977 371 10.1002/ehf2.14977 false true Reference 70713392 /api/reference/70713392 372. Abood 2025: Mavacamten in real-life practice: Initial experience at a hypertrophic cardiomyopathy centre., ESC Heart Fail., 12, p. 672, DOI: 10.1002/ehf2.14882 372 10.1002/ehf2.14882 false true Reference 70713393 /api/reference/70713393 373. Achim 2023: Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?., ESC Heart Fail., 10, p. 1570, DOI: 10.1002/ehf2.14272 373 10.1002/ehf2.14272 false true Reference 70713394 /api/reference/70713394 374. Azimi 2024: Identification of a novel likely pathogenic TPM1 variant linked to hypertrophic cardiomyopathy in a family with sudden cardiac death., ESC Heart Fail., 11, p. 3180, DOI: 10.1002/ehf2.14906 374 10.1002/ehf2.14906 false true Reference 70713395 /api/reference/70713395 375. Boleti 2024: Natural history and outcomes in paediatric RASopathy-associated hypertrophic cardiomyopathy., ESC Heart Fail., 11, p. 923, DOI: 10.1002/ehf2.14637 375 10.1002/ehf2.14637 false true Reference 70713396 /api/reference/70713396 376. Domain 2024: The D-HCM score, a new diagnostic tool for distinguishing hypertrophic cardiomyopathy from hypertensive cardiopathy., ESC Heart Fail., 11, p. 3924, DOI: 10.1002/ehf2.14988 376 10.1002/ehf2.14988 false true Reference 70713397 /api/reference/70713397 377. Erez 2024: Exercise limitation in hypertrophic cardiomyopathy: Combined stress echocardiography and cardiopulmonary exercise test., ESC Heart Fail., 11, p. 2287, DOI: 10.1002/ehf2.14776 377 10.1002/ehf2.14776 false true Reference 70713398 /api/reference/70713398 378. Farrant 2025: Considerations for drug trials in hypertrophic cardiomyopathy., ESC Heart Fail., 12, p. 1095, DOI: 10.1002/ehf2.15138 378 10.1002/ehf2.15138 false true Reference 70713399 /api/reference/70713399 379. Filippatos 2025: Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes., ESC Heart Fail., 12, p. 185, DOI: 10.1002/ehf2.14962 379 10.1002/ehf2.14962 false true Reference 70713400 /api/reference/70713400 380. Frustaci 2023: Hypertrophic obstructive cardiomyopathy caused by Fabry disease: Implications for surgical myectomy., ESC Heart Fail., 10, p. 3710, DOI: 10.1002/ehf2.14427 380 10.1002/ehf2.14427 false true Reference 70713401 /api/reference/70713401 381. Damy 2024: Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy., ESC Heart Fail., 11, p. 4314, DOI: 10.1002/ehf2.14971 381 10.1002/ehf2.14971 false true Reference 70713402 /api/reference/70713402 382. Garmany 2023: Clinical course of patients with hypertrophic cardiomyopathy away from tertiary referral care., ESC Heart Fail., 10, p. 1919, DOI: 10.1002/ehf2.14345 382 10.1002/ehf2.14345 false true Reference 70713403 /api/reference/70713403 383. Guo 2025: Systemic inflammation is associated with myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy., ESC Heart Fail., 12, p. 582, DOI: 10.1002/ehf2.15109 383 10.1002/ehf2.15109 false true Reference 70713404 /api/reference/70713404 384. Ha 2023: Effects of septal myectomy on left atrial and left ventricular function in obstructive hypertrophic cardiomyopathy., ESC Heart Fail., 10, p. 2939, DOI: 10.1002/ehf2.14481 384 10.1002/ehf2.14481 false true Reference 70713405 /api/reference/70713405 385. Hamers 2025: Trametinib alters contractility of paediatric Noonan syndrome-associated hypertrophic myocardial tissue slices., ESC Heart Fail., 12, p. 2321, DOI: 10.1002/ehf2.15173 385 10.1002/ehf2.15173 false true Reference 70713406 /api/reference/70713406 386. Li 2025: Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy., ESC Heart Fail., 12, p. 1256, DOI: 10.1002/ehf2.15135 386 10.1002/ehf2.15135 false true Reference 70713407 /api/reference/70713407 387. Lin 2024: Screening for Fabry disease in patients with left ventricular hypertrophy in China: A multicentre and prospective study., ESC Heart Fail., 11, p. 4381, DOI: 10.1002/ehf2.15065 387 10.1002/ehf2.15065 false true Reference 70713408 /api/reference/70713408 388. Liu 2024: Machine learning-driven diagnostic signature provides new insights in clinical management of hypertrophic cardiomyopathy., ESC Heart Fail., 11, p. 2234, DOI: 10.1002/ehf2.14762 388 10.1002/ehf2.14762 false true Reference 70713409 /api/reference/70713409 389. Miyashita 2023: Effects of bariatric surgery on cardiovascular-related acute care use in patients with hypertrophic cardiomyopathy., ESC Heart Fail., 10, p. 2438, DOI: 10.1002/ehf2.14414 389 10.1002/ehf2.14414 false true Reference 70713410 /api/reference/70713410 390. Ni 2023: A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy., ESC Heart Fail., 10, p. 2711, DOI: 10.1002/ehf2.14424 390 10.1002/ehf2.14424 false true Reference 70713411 /api/reference/70713411 391. Park 2024: Association of Fibrate use with clinical expression of hypertrophic cardiomyopathy., ESC Heart Fail., 11, p. 3972, DOI: 10.1002/ehf2.15004 391 10.1002/ehf2.15004 false true Reference 70713412 /api/reference/70713412 392. Ping 2024: Chlorogenic acid attenuates cardiac hypertrophy via up-regulating Sphingosine-1-phosphate receptor1 to inhibit endoplasmic reticulum stress., ESC Heart Fail., 11, p. 1580, DOI: 10.1002/ehf2.14707 392 10.1002/ehf2.14707 false true Reference 70713413 /api/reference/70713413 393. Radano 2024: Intramyocardial calcification in apical hypertrophic cardiomyopathy assessed using multimodality imaging: A case series., ESC Heart Fail., 11, p. 2415, DOI: 10.1002/ehf2.14775 393 10.1002/ehf2.14775 false true Reference 70713414 /api/reference/70713414 394. Saul 2024: Natural history and clinical outcomes of patients with hypertrophic cardiomyopathy from thin filament mutations., ESC Heart Fail., 11, p. 3501, DOI: 10.1002/ehf2.14848 394 10.1002/ehf2.14848 false true Reference 70713415 /api/reference/70713415 395. Tayier 2024: Different clinical presentation, cardiac morphology and gene mutations in two sisters with hypertrophic cardiomyopathy—A case report., ESC Heart Fail., 11, p. 2432, DOI: 10.1002/ehf2.14844 395 10.1002/ehf2.14844 false true Reference 70713416 /api/reference/70713416 396. Wang 2024: Biventricular outflow tract obstruction due to hypertrophy related to compound heterozygous variants in LZTR1., ESC Heart Fail., 11, p. 4450, DOI: 10.1002/ehf2.14944 396 10.1002/ehf2.14944 false true Reference 70713417 /api/reference/70713417 397. Zhang 2024: Influencing and prognostic factors of end-stage hypertrophic cardiomyopathy., ESC Heart Fail., 11, p. 4028, DOI: 10.1002/ehf2.15010 397 10.1002/ehf2.15010 false true Reference 70713418 /api/reference/70713418 398. Abdeldayem 2025: Long-Term Impact of Pregnancy on Clinical Outcomes in Individuals with Hypertrophic Cardiomyopathy., JACC Adv., 4, p. 101426, DOI: 10.1016/j.jacadv.2024.101426 398 10.1016/j.jacadv.2024.101426 false true Reference 70713419 /api/reference/70713419 399. Bertero 2024: Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population., Eur. J. Heart Fail., 26, p. 59, DOI: 10.1002/ejhf.3120 399 10.1002/ejhf.3120 false true Reference 70713420 /api/reference/70713420 400. Cui 2025: Phenotype-Based Classification of Obstructive Hypertrophic Cardiomyopathy Undergoing Myectomy., JACC Basic Transl Sci., 10, p. 568, DOI: 10.1016/j.jacbts.2024.12.016 400 10.1016/j.jacbts.2024.12.016 false true Reference 70713421 /api/reference/70713421 401. Desai 2025: Real-World Artificial Intelligence–Based Electrocardiographic Analysis to Diagnose Hypertrophic Cardiomyopathy., JACC Clin. Electrophysiol., 11, p. 1324, DOI: 10.1016/j.jacep.2025.02.024 401 10.1016/j.jacep.2025.02.024 false true Reference 70713422 /api/reference/70713422 402. Dominguez 2023: Mavacamten in obstructive hypertrophic cardiomyopathy—Are beta-blockers blocking part of its shine?., Eur. J. Heart Fail., 25, p. 271, DOI: 10.1002/ejhf.2768 402 10.1002/ejhf.2768 false true Reference 70713423 /api/reference/70713423 403. Earle 2024: Genetic Testing Yield and Clinical Characteristics of Hypertrophic Cardiomyopathy in Understudied Ethnic Groups: Insights From a New Zealand National Registry., Circ. Heart Fail., 17, p. e010970, DOI: 10.1161/CIRCHEARTFAILURE.123.010970 403 10.1161/CIRCHEARTFAILURE.123.010970 false true Reference 70713424 /api/reference/70713424 404. Fahmy 2024: Radiomics of Late Gadolinium Enhancement Reveals Prognostic Value of Myocardial Scar Heterogeneity in Hypertrophic Cardiomyopathy., JACC Cardiovasc. Imaging, 17, p. 16, DOI: 10.1016/j.jcmg.2023.05.003 404 10.1016/j.jcmg.2023.05.003 false true Reference 70713425 /api/reference/70713425 405. Goldie 2024: New Perspectives on Early Stage Hypertrophic Cardiomyopathy: Measuring What Matters., Circ. Heart Fail., 17, p. e012093, DOI: 10.1161/CIRCHEARTFAILURE.124.012093 405 10.1161/CIRCHEARTFAILURE.124.012093 false true Reference 70713426 /api/reference/70713426 406. Gaballa 2024: Long-Term Outcomes of Patients with Apical Hypertrophic Cardiomyopathy Utilizing a New Risk Score., JACC Adv., 3, p. 101235, DOI: 10.1016/j.jacadv.2024.101235 406 10.1016/j.jacadv.2024.101235 false true Reference 70713427 /api/reference/70713427 407. Laenens 2024: Heart failure risk assessment in patients with hypertrophic cardiomyopathy based on the H2 FPEF score., Eur. J. Heart Fail., 26, p. 2173, DOI: 10.1002/ejhf.3413 407 10.1002/ejhf.3413 false true Reference 70713428 /api/reference/70713428 408. Liang 2023: Advanced Heart Failure Therapies for Hypertrophic Cardiomyopathy., JACC Heart Fail., 11, p. 1473, DOI: 10.1016/j.jchf.2023.07.004 408 10.1016/j.jchf.2023.07.004 false true Reference 70713429 /api/reference/70713429 409. Lu 2025: Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using machine learning., Eur. J. Heart Fail., 27, p. 275, DOI: 10.1002/ejhf.3546 409 10.1002/ejhf.3546 false true Reference 70713430 /api/reference/70713430 410. Maron 2024: Safety and Efficacy of Metabolic Modulation with Ninerafaxstat in Patients with Nonobstructive Hypertrophic Cardiomyopathy., J. Am. Coll. Cardiol., 83, p. 2037, DOI: 10.1016/j.jacc.2024.03.387 410 10.1016/j.jacc.2024.03.387 false true Reference 70713431 /api/reference/70713431 411. Maron 2024: Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy., J. Am. Coll. Cardiol., 84, p. 1821, DOI: 10.1016/j.jacc.2024.09.003 411 10.1016/j.jacc.2024.09.003 false true Reference 70713432 /api/reference/70713432 412. Masri 2024: Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM., Eur. J. Heart Fail., 26, p. 1993 412 false true Reference 70713433 /api/reference/70713433 413. Masri 2024: Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy., J. Am. Coll. Cardiol., 84, p. 1806, DOI: 10.1016/j.jacc.2024.08.015 413 10.1016/j.jacc.2024.08.015 false true Reference 70713434 /api/reference/70713434 414. Masri 2024: Standard-of-Care Medication Withdrawal in Patients with Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM., J. Am. Coll. Cardiol., 84, p. 1839, DOI: 10.1016/j.jacc.2024.09.002 414 10.1016/j.jacc.2024.09.002 false true Reference 70713435 /api/reference/70713435 415. Maurizi 2023: Lifetime Clinical Course of Hypertrophic Cardiomyopathy., JACC Adv., 2, p. 100337, DOI: 10.1016/j.jacadv.2023.100337 415 10.1016/j.jacadv.2023.100337 false true Reference 70713436 /api/reference/70713436 416. Mentias 2023: Survival After Septal Reduction in Patients >65 Years Old with Obstructive Hypertrophic Cardiomyopathy., J. Am. Coll. Cardiol., 81, p. 105, DOI: 10.1016/j.jacc.2022.10.027 416 10.1016/j.jacc.2022.10.027 false true Reference 70713437 /api/reference/70713437 417. Moura 2023: Diagnosis and management of patients with left ventricular hypertrophy: Role of multimodality cardiac imaging. A scientific statement of the Heart Failure Association of the European Society of Cardiology., Eur. J. Heart Fail., 25, p. 1493, DOI: 10.1002/ejhf.2997 417 10.1002/ejhf.2997 false true Reference 70713438 /api/reference/70713438 418. Ommen 2024: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines., Circulation, 149, p. e1239, DOI: 10.1161/CIR.0000000000001250 418 10.1161/CIR.0000000000001250 false true Reference 70713439 /api/reference/70713439 419. Pierri 2024: Transcatheter Ablation of Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy., JACC Adv., 3, p. 100899, DOI: 10.1016/j.jacadv.2024.100899 419 10.1016/j.jacadv.2024.100899 false true Reference 70713440 /api/reference/70713440 420. Rader 2024: Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy., JACC Heart Fail., 12, p. 164, DOI: 10.1016/j.jchf.2023.09.028 420 10.1016/j.jchf.2023.09.028 false true Reference 70713441 /api/reference/70713441 421. Saberi 2025: Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy., JACC Heart Fail., 13, p. 102496, DOI: 10.1016/j.jchf.2025.03.040 421 10.1016/j.jchf.2025.03.040 false true Reference 70713442 /api/reference/70713442 422. Scolari 2024: Clonal haematopoiesis is associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy., Eur. J. Heart Fail., 26, p. 2193, DOI: 10.1002/ejhf.3408 422 10.1002/ejhf.3408 false true Reference 70713443 /api/reference/70713443 423. Sherrid 2023: Apical Aneurysms and Mid–Left Ventricular Obstruction in Hypertrophic Cardiomyopathy., JACC Cardiovasc. Imaging, 16, p. 591, DOI: 10.1016/j.jcmg.2022.11.013 423 10.1016/j.jcmg.2022.11.013 false true Reference 70713444 /api/reference/70713444 424. Sherrid 2024: Clinical Course and Treatment of Patients with Apical Aneurysms Due to Hypertrophic Cardiomyopathy., JACC Adv., 3, p. 101195, DOI: 10.1016/j.jacadv.2024.101195 424 10.1016/j.jacadv.2024.101195 false true Reference 70713445 /api/reference/70713445 425. Sherrod 2024: Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy., J. Am. Coll. Cardiol., 84, p. 1773, DOI: 10.1016/j.jacc.2024.08.014 425 10.1016/j.jacc.2024.08.014 false true Reference 70713446 /api/reference/70713446 426. Topriceanu 2025: Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial., Circ. Heart Fail., 18, p. e012393, DOI: 10.1161/CIRCHEARTFAILURE.124.012393 426 10.1161/CIRCHEARTFAILURE.124.012393 false true Reference 70713447 /api/reference/70713447 427. Troy 2023: Histopathology of the Mitral Valve Residual Leaflet in Obstructive Hypertrophic Cardiomyopathy., JACC Adv., 2, p. 100308, DOI: 10.1016/j.jacadv.2023.100308 427 10.1016/j.jacadv.2023.100308 false true /api/publication/36487681 Wilk Michał et al. Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022–2025. (2025) JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE 2308-3425 12 12<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >Wilk Michał </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Tymków Rafał </span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;36487681" target="_blank">Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022–2025</a></div> <div> <span class="journal-title">JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE</span> <span class="journal-issn">( <a target="_blank" href="https://portal.issn.org/resource/ISSN/2308-3425">2308-3425</a>)</span>: <span class="journal-volume">12</span> <span class="journal-issue">12</span> <span class="page"> Paper 484. </span> <span class="year">(2025)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="10.3390/jcdd12120484" target="_blank" href="https://doi.org/10.3390/jcdd12120484"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001646762700001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001646762700001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="105025668654" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105025668654"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="41440863" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41440863&dopt=Abstract"> PubMed </a> </span> </span> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;36487681&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 16 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 36487681</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">WoS-XML</span> </div> <div class="lastModified">Utolsó módosítás: 2026.04.01. 14:31 Vékony-Pap Lili (SZTE admin5) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Funding Agency and Grant Number: Wroclaw Medical University; Wroclaw Medical University, Poland [IDUB.A46B.24.002] Funding text: This research was funded by a grant from Wroclaw Medical University, Poland, number IDUB.A46B.24.002. The presented research results were funded by the Development Strategy of the Wroclaw Medical University entitled "UMW in the Light of Scientific Excellen...</pre> </div></div>